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The versatile electrospinning technique has been recognized as an efficient strategy to deliver 
active pharmaceutical ingredients and gained tremendous progress in drug delivery, tissue 
engineering, cancer therapy, and disease diagnosis. The current review presents numerous drug 
delivery systems fabricated through electrospinning regarding the carrier compositions, drug 
incorporation techniques, release kinetics and the subsequent therapeutic efficacy. Targeting 
for distinct applications, the composition of drug carriers vary from natural/synthetic 
polymers/blends, inorganic materials and even hybrids. Various drug incorporation approaches 
through electrospinning are thoroughly discussed with respect to the principles, benefits and 
limitations. To meet the various requirements in actual sophisticated in vivo environments and 
to overcome the limitations of single carrier system, feasible combination of multiple drug-
inclusion processes via electrospinning could be employed to achieve programmed, multi-
staged or stimuli-triggered release of multiple drugs. The therapeutic efficacy of the designed 
electrospun drug-eluting systems is further verified in multiple biomedical applications and is 














































































1. Introduction  
Since the first patent relating to the process and apparatus for artificial fibers using electric 
charges was approved in 1934,[1] electrospun architectures have been intensively investigated 
for many decades regarding the working principles, apparatus modifications, and diverse 
applications extending to texture industry, energy applications, and biomedical applications.[2] 
Ascribing to the various benefits associated with electrospun fibrous structures, such as fine 
fiber diameter down to nanometer, highly interconnected porous architecture, extreme high 
surface area and porosity, high loading capacity, high encapsulation efficiency, and feasibility 
for multifunctionlization, drug-loaded electrospun structures as novel drug delivery systems 
(DDS) are gaining increasing attentions in multiple biomedical applications (e.g., drug delivery, 
tissue engineering and cancer therapy).[3]   
In principle, micro/nanofibers can be continuously produced when polymeric jets are ejected 
from viscoelastic solutions and further stretched and elongated by electrostatic repulsion forces 
between surface charges.[4] By carefully manipulating on the apparatus and parameters, fiber 
diameter distribution, pore size, porosity and spatial arrangement can be controlled and adjusted; 
moreover, fibrous meshes with secondary structures such as porous fiber surfaces, core-shell or 
hollow tubular structures can be further designed and generated.[2c, 4b] Such exceptional control 
on morphological and dimensional variations provides numerous possibilities to carry and 
entrap a variety of drug molecules within the electrospun fibers. In case of materials and 
compositions, either single or multiple drugs can be incorporated into polymeric matrix or 
organic/inorganic composite matrix. Through technical management, drugs can be either 
evenly distributed within the fibers or locally concentrated in the outer or inner layer of fibers.[5] 
In view of release behavior, drugs could be released in a rapid, sustained, bi-phasic or zero-





































































DDS, electrospinning has its intrinsic advantages to overcome the challenges existing in 
contemporary pharmaceutical research, such as difficulty for location-specific targeting 
delivery, poor aqueous solubility of hydrophobic drugs (which amounted to nearly 40% of 
marketed drugs), and chemical and physical degradation of complex and bioactive molecules.[7] 
Obviously, implantable therapeutic drugs-loaded electrospun scaffolds can be feasibly operated 
for targeted delivery at specific tissues or organs; this top-down technique is able to molecularly 
disperse hydrophobic drugs in the nanofibers or to stabilize the drugs in the amorphous form, 
yielding a significant increase in the aqueous dissolution rate.[8] In case of sustained release of 
sensitive species, electrospun fibermats as stable formulations could act as a storage matrix and 
protect them from the light, heat or degradation medium, and thus, ameliorate the possible 
degradation.[7a] 
In general, the electrospinning technique demonstrates its great potential to create implantable 
drug carriers, which could be further utilized for various biomedical applications requiring drug 
delivery function. Its history, fundamental principle, governing of parameters have been 
thoroughly reviewed and discussed in numerous literatures.[2a, 2c, 3a, 4b] However, the reported 
reviews related to electrospun DDS are either out-of-date or within limited application fields. 
A timely and comprehensive review focusing on the electrospun DDS for various biomedical 
applications is necessary. The current article will highlight the advances of electrospun DDS 
achieved in the past few years to meet clinical needs, mainly in simple drug delivery, tissue 
engineering and cancer therapy. The major purposes are: 1) to briefly discuss the fabrication of 
DDS through electrospinning, in terms of materials, drugs, techniques and drug release kinetics; 






































































2. Fabrication of Electrospun Drug Delivery Systems and the Release Kinetics 
Two key elements, matrix materials and therapeutic drugs, build up the DDS for the intended 
applications. Both components, and the adopted strategies to combine them, have decisive 
influence on the release behavior, including drug release duration and the trend of profiles. The 
most studied materials and drugs used in electrospun DDS are overviewed in this section, and 
their influences on the drug release behavior are also discussed.    
 
2.1 Materials and Drugs 
Although the versatile electrospinning technique enables the nanofiber formation from more 
than 200 polymers,[2a] more specific requirements in different DDS could further narrow down 
the choosing pool of polymer matrix. Angelova and Hunkeler[9] thoroughly categorized the 
polymeric biomaterials and proposed a flowchart as guidelines for rationalized polymer 
selection regarding the structure-property-application relationships. In this review, only the 
materials and drugs frequently studied in recent electrospun DDS will be briefly summarized. 
 
2.1.1 Structural materials for electrospun DDS 
Biocompatible polymers with diverse hydrophilicity/hydrophobicity, permeability, and 
mechanical properties are considered as promising candidates to load specific drugs aiming for 
distinct therapeutic efficacy. Target application is the primary consideration to determine the 
compositions of DDS.  
In fast dissolving drug delivery systems (FDDDS), drug dosage forms are supposed to rapidly 
disintegrate in the oral cavity, therefore hydrophilic biopolymers are considered as optimal 
candidates to carry the drugs, such as poly (vinyl alcohol) (PVA)[10] , polyvinylpyrrolidone 





































































electrospun to form patches containing antifungal agents due to its biocompatibility and 
mucoadhesive property.[13] The varying cross-linking degrees of gelatin allow the adjustable 
and sustained release of antifungal agents in the oral cavity to maintain the therapeutic level.[14] 
To fabricate an oral formulation for drug releasing via the sublingual route, PVA/sodium 
alginate blend was chosen as the patch matrix to enable sustained drug release over 10 h.[15] 
Due to the pH sensitive feature, some smart materials, such as shellac and Eudragit S100, can 
prevent the drug release in low pH and allow rapid drug release in neutral pH condition, making 
them highly applicable for oral colon-targeted drug delivery.[16] Biodegradable and 
biocompatible fibrous patches, such as poly(lactic-co-glycolic acid) (PLGA),[17] cellulose 
derivatives,[18] polyurethane (PU),[19] chitosan,[20] PVP,[21] PVA,[22] polycaprolactone (PCL),[23] 
and polylactic acid (PLA) family,[24] can be produced from electrospinning to administrate 
drugs via transdermal drug delivery, since the high porosity and surface area of electrospun 
fibers could greatly enhance the drug diffusion and thus drug accumulation efficiency in 
comparison to the cast films.[17a] 
A wide range of polymers were reported to act as the matrix in drug carriers for tissue 
engineering, which required controlled drug release and simultaneous physical support for 
tissue regeneration.[25] The polymeric matrix is supposed to degrade gradually as the neotissue 
growth and therapeutic agents will be subsequently released from the matrix via both diffusion 
paths and matrix degradation.[26] Natural polymers, such as collagen, chitosan, gelatin and 
hyaluronic acid attracted great attentions due to their unique cellular affinity. However, their 
applications were mainly limited by the inadequate mechanical strength and low stability in 
physiological conditions.[25] Synthetic biopolymers represent the majority materials applied in 
both tissue engineering and drug delivery applications, due to the feasible tunability in 





































































requirements.[27] Polymers, such as PLA/PLLA,[28] PLGA,[29] polyhydroxyalkanoates 
(PHAs),[30] and PCL,[31] were the representatives and extensively studied in recent years.    
Nevertheless, single polymer usually cannot fulfill the requirements in the complex in vivo 
environments, therefore polymer blending is a simply approach to adjust the physicochemical 
features and degradation rates of the fabricated scaffolds. For example, the blending of stiff and 
flexible polymers in the scaffolds could combine and balance the stiffness and elasticity;[32] the 
blending of natural polymers with synthetic polymers endowed the scaffolds with both cell-
affinity feature and high mechanical properties;[31a, 33] the blending of varying ratios of water-
soluble materials with hydrophobic polymers can adjust the medium penetration rate and 
subsequent drug diffusion rate and release profiles.[34] For instance, in the study of Zhu et al.[34a], 
up to 50 wt.% of PEG was blended with PLLA fibers to adjust the release behavior of 
papaverine. In vitro drug release studies showed that blended fibers with PEG ratios of 20%, 
30%, 40% and 50% exhibited complete drug release on days 13, 11, 8 and 4, respectively.  
Most electrospun drug carriers are fabricated from polymers due to their flexibility and feasible 
processability. However, in some fields, e.g., disease diagnosis, inorganic nanofibers exhibited 
better performances owing to their unique physiological performances. For instance, ZnO 
nanofibers were reported to provide an excellent electrical conduction path between biomarkers 
and electrodes, and enabled the creation of a biodevice with hypersensitivity.[35] Ali et al.[36] 
reported the fabrication of mesoporous ZnO nanofibers through electrospinning of the precursor 
solution and created a highly efficient and reproducible immunosensor by conjugating the ZnO 
nanofibers with a biomarker (anti-ErbB2; epidermal growth factor receptor 2) to diagnose the 
early breast cancer. This platform should also apply for other cancer detection through 
conjugation with corresponding biomarkers, making it a superior immunosensor with higher 





































































nanotubes with bimodal meso- and micro-pores were synthesized through modified 
electrospinning and then loaded with Pt catalyst to directly monitor simulated diabetic breath. 
Unlike polymer nanofibers, inorganic nanofibers or tubes were usually fabricated through 
electrospinning in combination with a sacrificial templating route. Therefore, the precise 
control on post-treatments after electrospinning, including drying and calcination, was able to 
customize the fiber morphology and therefore modulate the resultant functions.[38] Furthermore, 
drug delivery systems based on polymeric/inorganic composite materials were fabricated to 
combine the advantageous merits of both organic and inorganic materials. [39] 
 
2.1.2 Smart materials for electrospun DDS  
Stimuli-responsive polymers play important roles in DDS due to their rapid changes in 
conformation, solubility, morphological or mechanical performances when exposed to the 
external stimuli, such as pH, temperature, light, ultrasound, electric or magnetic field.[40] The 
high surface-to-volume ratio and porosity of electrospun scaffolds allow fast diffusion of 
stimulus and rapid contact with fibers resulting hypersensitive responses. Electrospinning of 
these stimuli-responsive polymers thus opened-up new horizons for on-demand DDS in many 
applications, e.g. oral drug delivery, tropical cancer drug administration or sequential drug 
release in tissue engineering.[40-41]  
Eudragit polymers represent a type of pH-sensitive polymers that were developed based on the 
functionalization of methacrylic acids. By varying the composition ratios, Eudragit polymers 
soluble in fluids of distinct organs at different physiological pH were synthesized and widely 
applied in oral drug formulations.[42] For instance, Eudragit E 100 can only be dissolved in 
gastric fluid up to pH 5, Eudragit L 100 (EL100) was designed to be dissolved in intestinal 





































































prepared ES100 (shell)/lecithin-diclofenac sodium(core) and ES100(shell)/indomethacin (core)  
fibrous scaffolds to protect the drug from acid gastric fluid and achieve colon-targeted release. 
Han et al.[43] comparatively studied the pH-responsive release of two model drugs from EL100 
(core)/ES100 (shell) and ES 100 (core)/EL100 (shell) core-shell fibers and demonstrated multi-
pH responsive and selective pH-responsive performances of the different Eudragit polymer 
combinations (Figure 1a). Additionally, new class of pH sensitive copolymers, such as poly(4-
vinylbenzoic acid-co-(ar-vinylbenzyl)trimethylammonium chloride) [poly(VBA-co-VBTAC)], 
was synthesized and electrospun into nanofibers to deliver ciprofloxacin in response to acid, 
neutral or basic conditions.[45]  
Poly (N-isopropylacrylamide) (PNIPAM) is widely applied in thermos-responsive systems 
since it is able to reversibly switch its swelling state below lower critical solution temperature 
(LCST, at 32°C) and the deswelling state above LCST.[46] Li et al.[47] embedded P(IPAAm- co-
AAc) nanogels within the PCL shell of drug-loaded electrospun fibers. The deswelling of 
embedded nanogels above 40°C created cavities and diffusion paths around the gels and 
allowed rapid drug release, whereas the re-swelling of nanogels then closed the cavities 
resulting delayed drug release (Figure 1b). Similarly, electrospun PNIPAAm/ethyl cellulose 
fibers loaded with ketoprofen were applied to achieve on-demand drug release in responsive to 
temperature.[48] A copolymer of poly(N-isopropylacrylamide-co-methacrylic acid) (PNIPAM-
co-MAA), which combined the stimuli-responsive features of both PNIPAM and methacrylic 
acids, is responsive to both temperature and pH simultaneously.[49] In a study of Yuan  et al. 
[50], electrospun chitosan-graft-poly(N-isopropylacrylamide) (CTS-g-PNIPAAm) fibrous 
scaffolds showed responsive feature to both pH and temperature, since chitosan was reported 
to be pH-sensitive owing to the ionization of the amino groups. Li et al.[51] incorporated gold 





































































fibers through electrospinning, thereby fabricating hybrid scaffolds with near-infrared (NIR) 
light-driven and subsequent temperature-triggered drug release. In their study, the heat-up of 
gold nanoparticles upon exposure to NIR light could initiate the shrinkage of PNIPAM and then 
speed up the drug release. 
In a study of Song et al.,[52] the authors proposed that the ultrasound irradiation could trigger 
the on-demand drug release from a dual-drug-loaded PLGA composite fibers containing both 
fluorescein (FLU) and rhodamine B-loaded mesoporous silica nanoparticles (RHB loaded 
MSNs) (Figure 1c). The enhanced drug release both from PLGA fibers and MSNs was 
attributed to the elevated temperature, which can be controlled through ultrasonic stimulation. 
By selectively manipulating the ultrasonic powers and pulsed cycles, on-demand drug release 
can be easily achieved.  
Han et al.[53] synthesized a self-immolative polymer (SIP) and then fabricated SIP/ 
polyacrylonitrile (PAN) fibers with PVP/dye in core section through co-axial electrospinning 
(Figure 1d). Due to the extremely high surface area, nano-sized diameter and high porosity, 
SIP in the fiber shell could display very fast and responsive depolymerization upon external 
stimuli, resulting in on-demand drug release.  
The magnetic-filed responsive feature was normally introduced by magnetic nanoparticles, i.e., 
iron oxide nanoparticles (IONPs). Wang et al.[54] created drug-loaded magnetic fibers by 
loading IONPs into PCL shell and confining ketoconazole within PCL hollow core through co-
axial electrospinning. The release study showed that the introduction of an auxiliary magnetic 
field could accelerate the ketoconazole release due to the intensified motion of molecules 





































































Additionally, the promising applications of other electrospun systems for tumor-triggered drug 
release[55], and inflammation-sensitive release[56] were also explored. These systems are further 
discussed later in this review.  
 
Figure 1. Several representative studies of stimuli-responsive drug release systems via 
electrospinning. (a) Electrospun core-shell fibers from pH-responsive polymers: (1) ES 
100(shell)/EL100 (core) and (2) ES100 (core)/EL100 (shell). Reproduced with permission;[43] 
Copyright 2017, American Chemical Society. (b) Electrospun core-shell fibers using 
temperature-sensitive P(NIPAM-co-AAc) nanogels as valve to achieve temperature-responsive 
drug release. Reproduced with permission;[47] Copyright 2015, John Wiley and Sons. (c) 
Ultrasound-triggered drug release from PLGA composite fibers. Reproduced with 





































































polymer/PAN core-shell fibers for stimuli-responsive drug release. Reproduced with 
permission;[53] Copyright 2017, American Chemical Society. 
 
2.1.3 Multiple drugs involved in electrospun DDS 
As the key component in DDS, drugs are also known as active pharmaceutical ingredients 
(APIs), which have the responsibility to achieve satisfactory therapeutic efficacy. In current 
biomedical applications, APIs not only indicate the traditional small-molecule drugs, but also 
refer to all the ingredients that have desired therapeutic functions.  
To achieve antibacterial function, a large range of antibiotics were encapsulated into fibers 
through electrospinning, such as tetracycline, cefoxitin, amoxicillin, gentamycin or 
ciprofloxacin.[57] The simple process of electrospinning usually allows the feasible addition of 
large amount of antibiotics; and the drug inclusion could also affect the solution properties, 
such as viscosity, conductivity and thereby influence the fiber structures. However, a higher 
risk of burst release often associated with the antibiotics/polymer systems due to the 
incompatibility between hydrophilic drugs and hydrophobic polymers.[31a] Moreover, the 
incorporation and release of silver, titanium dioxide, and zinc oxide nanoparticles from 
electrospun fibers have also been investigated to prevent the inflammation and infections.[57-58] 
In addition to the antibacterial function, some other biological enhancements could also be 
achieved, such as the improved osteoconductivity introduced by zinc oxide for an application 
in periodontal membrane.[58b] 
Anti-cancer drugs are another group of APIs which were intensively investigated in drug carrier 
systems for cancer therapy. Electrospun fibers containing paclitaxel, doxorubicin, camptothecin, 
hydroxycamptothecin, bortezomib, temozolomide, titanocene dichloride, daunorubicin, 





































































skin cancer, leukemia, and avoid tumor recurrence.[34b, 55, 59] Additionally, IONPs were co-
incorporated with bortezomib by Sasikala et al. [55b] to achieve combined hyperthermia therapy 
and chemotherapy. In a study of Zhang et al.[60], multi-walled carbon nanotubes were co-
blended with doxorubicin in PLLA fibers to combine photothermal therapy and chemotherapy.  
Growth factors, peptides and genes representing the biologically active molecules could also 
be encapsulated and delivered through electrospun fibers to regulate and modulate the 
biological signals between cells and the extracellular matrix (ECM) for tissue regeneration.[61] 
For instance, basic fibroblast growth factor (bFGF) and endothelial growth factor (EGF) were 
embedded in collagen and hyaluronic acid fiber to accelerate epithelialization and vasculature 
sprouting, whereas vascular endothelial growth factor (VEGF) and platelet-derived growth 
factor (PDGF) were expected to induce blood vessels maturation.[62] Recombinant human 
transforming growth factor-b1 (rhTGF-b1) was confined within PCL fibers to stimulate 
chondrogenic differentiation of  bone marrow-derived stem cells (BMSCs).[63] Nerve Growth 
Factor (NGF)-loaded PCL fibers were proved to sustainably induce the neuronal 
differentiation.[64] In a study of Li et al.[65] to repair critical-sized rat calvarial defect, bone 
morphogenetic protein-2 (BMP-2) was loaded to obtain osteoinductivity. For gene delivery, 
nonviral vehicles such as plasmid DNA or small nucleic acids and viral vehicles such as 
recombinant adeno-associated viral (AAV), have been promisingly applied in gene therapy. 
Aiming for vascular tissue regeneration, Zhou et al.[66] loaded microRNA-126 complexes 
within the inner layer of a bilayer tubular scaffold through dual-power electrospinning since 
microRNA-126 could essentially manipulate the vascular integrity and angiogenesis via 
regulating the angiogenic growth factors. James et al.[67] included microRNA-29a into cross-
linked gelatin fibers to increase the synthesis and deposition of ECM for bone tissue 





































































Gu et al.[68] incorporated AAV encoding green fluorescent protein (GFP) into polyester 
urethane urea fibers as elastic epicardial patch to restore cardiac function. The 
biomacromolecules usually are chemically unstable and have short half-life in vivo. 
Additionally, the harsh conditions in conventional electrospinning may harm their bioactivity 
and cause denaturation. Thus, modified electrospinning technique, such as co-axial 
electrospinning was considered as a superior option to avoid the denaturation.  
Living cells have also been successfully encapsulated into biomedical polymer fibers through 
co-axial electrospinning to form cell-bearing fibers or scaffolds.[69] The cell suspensions within 
inner needle were safely shielded and protected by the outer polymer solutions and in vitro and 
in vivo studies certified well-maintained functions of the viable cells during and after the 
electrospinning.[69c]   
 
2.2 Drug Incorporation Techniques  
As one of the major factors for determining release kinetics, the location of drugs within fiber 
matrix can be simply arranged through different loading techniques. The drugs can be included 
onto the surface, within surface vicinity, throughout the whole fiber, exclusively within shell 
layer or core layer via surface immobilization, blend electrospinning, co-axial electrospinning 
or emulsion electrospinning. A secondary barrier could also be added to the system to further 
prolong the drug release and provide the possibility for simultaneous release of multiple drugs. 
The current section will focus on a comprehensive elaboration on these different drug 







































































2.2.1 Surface immobilization 
Surface immobilization, also referring to surface coating or surface functionalization, is 
regarded as one of the easy approach to absorb the drug molecules onto the fiber surfaces 
through chemical (covalent bonding) or physical interactions (electrostatic interaction, van der 
Waals interaction or hydrogen bonding, etc.).[70] As a result of the high surface-to-volume ratio 
of electrospun fibers, numerous adhesion sites exist for drug molecules to attach and modify 
the resultant performances, such as wettability, cellular adhesion and genes expression.[71] 
Multiple methods were developed to achieve the functionalization via various bonding. Table 
1 lists several recent electrospun drug-loaded scaffolds via surface immobilization and the 
associated highlights and applications are also described. 
The common method for feasible coating is to immerse fibers in target solutions for passive 
adsorption of biomolecules. Yao et al. [33a] dip-coated the PCL/chitosan scaffolds with heparin 
via ionic bonding between heparin and chitosan for vascular grafts application, resulting in 
sustained release of heparin over 37 days. Moreover, increasing the chitosan ratio could further 
efficiently prolong the drug release. Qiu et al.[72] functionalized PCU fibers with plasma 
treatment and subsequent conjugation of heparin via end-point immobilization. Polydopamine 
(pDA) chemistry is one of the popular approaches to immobilize proteins, peptides and 
antibodies onto hydrophobic fiber mats to enhance the cell affinity, cell-matrix interactions and 
introduce specific bio-signals (Figure 2a).[28b, 29c, 55b, 73] Oxidative self-polymerization of 
dopamine into pDA on fiber surface could provide abundant hydroxyl and amine groups to 
covalently bond with biomolecules under weak alkaline conditions. In the works of Lee et al. 
and Cho et al. [28b, 29c], bone-forming peptide 1 (BFP1) and bone morphogenetic protein-2(BMP-
2) were subsequently immobilized onto PLGA and PLLA fibrous fibers, respectively, after 





































































be lasted up to 28 days with minimum burst release.[28b] PDA coating itself was also reported 
to be biocompatible and to enhance cell proliferation. Taskin et al.[31c] collected the electrospun 
PCL fibers in dopamine solution bath to form 3D coiled PCL fiber scaffolds with in-situ 
polymerized pDA coatings. In addition to pDA, a di-amino-poly (ethylene glycol) linker (di-
amino-PEG), was also employed to act as an intermediate cross-linker to covalently bond mucin 
onto the fibrous scaffolds.[74] This conjugated mucin was more stable than simply absorbed 
mucin under static and flow conditions.  
In addition to biomolecules, organically modified glass (ormoglass) layer containing bioactive 
ions was also covalently immobilized onto fiber surface through four functionalization steps: 
NaOH hydrolysis, ethyl(dimethyl-aminopropyl)carbodiimide/N-hydroxysuccinimide 
(EDC/NHS)treatment, immersion in 3-aminopropyltriethoxysilane (APTES) solution and 
subsequent ormoglass coating (Figure 2b).[71c] The hybrid organic/inorganic glass coating 
remarkably enhanced the mechanical performances, wettability and roughness. Moreover, 
calcium ions were sustained released for 14 days despite the burst release in the first day.  
Jia et al.[75] employed an inkjet printing to precisely deposit the growth factors onto fiber 
surfaces (Figure 2c). Through optimization of printing parameters, the biomolecules and 
subsequent cellular distribution were spatially organized in designed patterns. Although no 
strong interactions occurred, the deposited growth factors were still remained on the fibrous 
scaffold for more than 1 week, enabling the successful regulation function of TGF-β1 on the 
fibroblast differentiation. In addition, the precisely controlled deposition of biomolecules 
enforces the formation of biomolecular fibrous network, which could essentially mimic the 





































































Since the immobilizations usually only occurred on the surface or near surface vicinity, the 
incorporation of drugs or biomolecules would not alter the overall physical performances and 
the degradation properties of the original electrospun fibers. Additionally, post-immobilization 
of biomacromolecules could feasibly avoid the denaturation caused by the harsh condition of 
organic solutions. 
 
Figure 2. (a) Peptides immobilization onto PLGA fibers surface through pDA chemistry. 
Reproduced with permission;[29c] Copyright 2013, Elsevier B.V. (b) Bioactive glass phase was 
coated onto the electrospun fibers through a four-step process. Reproduced with permission;[71c] 
Copyright 2015, Royal Society of Chemistry. (c) Patterned biomolecule deposition onto 
electrospun fibermats via inkjet printing. Reproduced with permission;[75] Copyright 2017, John 








































































Table 1. Representative electrospun DDS via surface immobilization and the associated 
highlights and applications. 




Heparin  Drug immobilization via strong ionic bonding 
between heparin and chitosan;  
Burst release in 1 d followed by sustained release 
until 37 d. 
Vascular grafts [33a] 
PCL/ 
Collagen 
SDF1α Growth factors were embedded in radically 
aligned fibers through collagen-binding domain; 








20.4% of AuNPs were rapidly released in 1 d and 
then sustained released for 14 d, exhibiting 
striking ability to remedy multidrug-resistant 
bacteria wound infections. 
Wound healing [33c] 
PLGA Polydopamine 
Bortezomib  
Bortezomib conjugation onto the fiber surface 
through dopamine coating;  
70% vs 20% of drug was released in the first 12 
h at pH 5.5 vs 7.4. 




Sustained release of Ca2+ ions for over 16 d;  





PCU Heparin PCU fibers were treated by plasma and then 
conjugated with heparin via end-point 
immobilization; 
Conjugated heparin dramatically improved the 
patency of vascular grafts, the early stages of 
endothelialization and graft integration in vivo. 
Vascular graft [72] 
PLGA Polydopamine, 
BFP1 
Significant increase of newly formed bone 
volume after implantation of pDA-BFP1-coated 




PLLA Polydopamine,  
BMP-2 







peptide (OP)  
After 8 h of polydopamine coating, 80% of 
immobilized OP can be retained on the fiber 




PCL Polydopamine 3D-coiled fibrous scaffolds with polydopamine 
















































































In comparison to absorbed BSM, conjugated 
BSM on the fiber surface significantly improved 
the patency of vascular grafts, prevented 
thrombosis and graft occlusion. 
Vascular graft [74] 
PCL/ 
Collagen 
BSA A biomolecule network with designed 
biomimetic patterns, formed on the fiber 
substrates by inkjet printing. 
Cancer therapy [75] 
PLLA Fibronectin Fibronectin coating on fibers effectively 






Self-assembled RGD/YIGSR coating on fiber 
surface highly improved the cell adhesion and 
survival of Schwann cells, promoted axonal 




PCL Azithromycin  Drugs immobilization through solvent 
evaporation technique; 
All drugs were rapidly released in the first 24 h 









Immobilization of Cys-KR12 on to electrospun 
silk fibers through EDC/NHS and thiol-
maleimide click chemistry; 
Antibacterial effect maintained for 3 wk. 
Wound healing [78] 
PCL, polycaprolactone; SDF1α, stromal-cell-derived factor-1α; APA-coated AuNPs, (6-
aminopenicillanic acid, APA)-coated gold nanoparticles; PCU, polycarbonate-urethane; PLGA, 
poly(lactic-co-glycolic acid); BFP1, bone-forming peptide 1; PLLA, poly(L-lactide); BMP-2, bone 
morphogenetic protein-2; OP, osteogenic peptide derived from BMP-2; PLCG, poly(L-lactide-co-
caprolactone-co-glycolide); BSM, bovine submaxillary mucin; EDC, 1-ethyl-3-(3 dimethylaminopropyl) 
carbodiimide hydrochloride; NHS, N-hydroxysulfosuccinimide; PEG, poly(ethylene glycol); BSA, 
bovine serum albumin; RGD, arginine-glycine-aspartic; YIGSR, tyrosine-isoleucine-glycine-serine-
arginine. 
 
2.2.2 Blend electrospinning 
Blend electrospinning is a one-step method to embed or encapsulate drug molecules into fiber 





































































polymers. Blend electrospinning was the earliest attempt to form drug formulations through 
electrospinning, reported by Kenawy et al.[79] in 2002. They claimed that the drug release in 
electrospun fibers was much faster than the cast films due to the high surface-volume ratio of 
electrospun membranes and the drug release kinetics can be modulated through adjusting the 
polymer compositions. Soon after, Zeng et al.[80] investigated the decisive factors determining 
the release kinetics of blending fibers. Their study firstly revealed that the drug solubility and 
drug-polymer compatibility practically influenced the drug distribution throughout the fibers 
and thus the release profiles. In blending systems, a constant and stable drug release can only 
be achieved in lipophilic drug/lipophilic polymer or hydrophilic drug/hydrophilic polymers 
systems. Thereafter, numerous drug/polymer systems were fabricated by blending and their 
drug delivery functions were widely explored.[31a, 34a, 81] Table 2 summarizes the recent drug-
laden fibers through blend electrospinning. Fast drug release for such as 2 h or sustained release 
for such as 91 days can be accomplished via blend electrospinning when the appropriate 
drug/polymer were chosen.[81-82] By doping an enzyme-sensitive prodrug (poly(ibuprofen)) into 
polymer poly(hydroxyethyl methacrylate) (PHEMA) fibers via blend electrospinning (Figure 
3a), Pan et al.[83] successfully managed a polymer degradation-synchronized drug release for 
14 weeks (accelerated drug release when polymer underwent self-catalyzed degradation). Apart 
from the drug molecules, (6-aminopenicillanic acid, APA)-coated gold nanoparticles (AuNPs) 
were also doped into PCL/gelatin fibers to resist multidrug-resistant bacteria and promote 
wound healing (Figure 3b).[33c]  
Obviously, blending is the simplest strategy to achieve drug delivery through electrospinning. 
The limitation of blend electrospinning is that biomolecules may denature in case of harsh 







































































Figure 3. (a) Prodrugs were encapsulated in polymer fibers through blend electrospinning. 
Reproduced with permission;[83] Copyright 2015, Elsevier B.V. (b) PCL/gelatin fibers 
containing modified gold nanoparticles were fabricated through blend electrospinning. 
Reproduced with permission;[33c] Copyright 2017, American Chemical Society. 
 
Table 2. Representative electrospun DDS via blend electrospinning and the associated 
highlights and applications. 
Materials Drugs Highlights Applications Ref. 
PCL/ 
gelatin 
MNA An initial burst release in 3 d (60%) and sustained 





PEG blend  
Papaverine Papaverine can be rapidly released in the first 2~7 
d and then sustainably released until 14 d by 






Niclosamide Gradual release of 40% of niclosamide over 21 d, 
following the Korsmeyer–Peppas model. 




Cisplatin Linear drug release over 90 d due to the blend 





BPU  Dipyridamole Sustained Drug release over 91d due to the good 
compatibility; The higher the drug ratio, the 
slower the drug release. 





































































PCL PIBU  Incorporation of enzyme sensitive prodrug PIBU 
through blend electrospinning; 
Combination of initial enzyme-triggered release - 
moderate release of anti-inflammatory drugs and 
degradation-synchronized drug release in the 








Nattokinase Core-shell structure with thermal-responsive 
shell was self-assembled during the 
electrospinning; 
The thermal-responsive shell allowed faster drug 
release above the phase transition temperature 
(32°C), therefore resisted the platelet adhesion 
and facilitated red blood cells capture. 
To capture red 






YIGSR and RGD 
Two adhesive peptides were uniformly 
distributed on the surface and inside of fibers, 







Fabrication of multilayer scaffolds with dual-
drug-loaded layers through co-electrospinning; 










MiR-126  Fabrication of multilayer tubular electrospun 
scaffolds through dual-power electrospinning; 




Gelatin MiR-29a  Burst release of miR-29a in 2 h and then sustained 







VEGF and bFGF Dual-growth factors release; 
Burst release of both growth factors in 7 h and 









PVA Antifungal Cm-p1  Burst release in 2 h and following sustained 






Fiber fabrication through in-situ cross-linking of 
gelatin, pDA and antibiotics via strong interfacial 
interactions, resulting in extended antibacterial 









































































PLA Paclitaxel Drug release in concentration-dependent manner; 
Scaffolds with drug ratios from 0.02% to 3.26% 







TSA Sustained release of less than 35% of TSA from 
aligned fibers over 90 h, following the Higuchi 
equation; 
Aligned fiber orientation delayed the drug release 




PEO, polyethylene oxide; PGC-C18, poly(caprolactone-co-glycerol-monostearate); BPU, 
biodegradable elastic polyurethane urea; PIBU, poly (ibuprofen); PNIPAAm, poly(N-
isopropylacrylamide); PELCL, poly(ethylene glycol)-b-poly(L-lactide-co-e-caprolactone); mir-126, 
microRNA-126 complexes; miR-29a, microRNA-29a complexes; PLCL, poly(L-lactide-co-
caprolactone); PEOz, poly (2-ethyl-2-oxazoline); VEGF, vascular endothelial growth factor; bFGF, 
basic fibroblast growth factor; Cm-p1, cencritchis muricatus peptide 1; TSA, Trichostatin A. 
 
 2.2.3 Co-axial/ tri-axial electrospinning 
High initial burst drug release often occurred in the fibers fabricated through direct blend 
electrospinning. The locally elevated drug concentration could cause cellular toxicity, and the 
short release period could not ensure the healing efficacy in many cases. Therefore, there is a 
demand for innovative modifications and alternatives to alleviate the burst release. Co-axial 
electrospinning, which was firstly reported by Sun et al.[93] in 2003, utilized a spinneret 
consisting of two concentrically aligned capillaries to push immiscible inner and outer solutions 
simultaneously for generating core-shell fibers. The second separate core nozzle enables the 
encapsulation of sensitive, water-soluble and bioactive molecules possible, and the deleterious 
effects from organic solvents can be avoided. Even unspinnable drug solution can be utilized 
in co-axial electrospinning, thus ultra-high drug loading into the central section could be 





































































Table 3 summarizes the recent drug-laden fibers through co/tri-axial electrospinning. Various 
chemicals and bioactive agents for drug delivery and tissue engineering, such as growth factors, 
nucleic acids and living organisms, can be incorporated into the core section without losing 
their functions.[95] When shielded from the shell polymer, central-located bioactive agents can 
only be released through nano-path diffusion and/or shell polymer degradation. Therefore, by 
varying the composition of shell polymers, sustained release or sequential release of multiple 
drugs can be feasibly achieved.[96] For instance, rapid drug release prolife was shown in case of 
hydrophilic polymeric shell and slow and sustained release profile can be obtained in case of 
hydrophobic polymeric shell.[44, 68, 94]. Additionally, the release time-scale can be adjusted 
simply through altering the fiber surface texture and shell thickness (relevant to feeding rate of 
outer and inner solution).[97] Moreover, the interactions between inner and outer solutions were 
also reported to affect the release kinetics. Angkawinitwong et al.[98] discovered that the pH of 
core solutions could greatly influence the core-sheath structure and thus the release kinetics 
when they incorporated bevacizumab into PCL fibers through co-axial electrospinning. As 
shown in Figure 4a, the positively charged bevacizumab could uncontrollably migrate from the 
core solution to the PCL sheath solution, resulting in the inhomogeneous distribution of drug 
in both shell and core section, and thus a first order release up to 18 days. However, the neutral 
charged bevacizumab could be finely confined in the core section, forming a well-defined core-
shell structure, and thus a zero-order release of drug up to 60 days.  
To meet the demand of body temperature-stimuli responsive drug release, Li et al.[47] created a 
thermally switched drug release device through co-axial electrospinning. Thermally responsive 
nanogels, which were embedded into the PCL shell to act as valves, generated cavities as paths 
for the diffusion of encapsulated drugs during the shrinking and swelling at above or under 





































































provides more possibilities to modify the materials, fiber structures and release kinetics. Yu et 
al.[99]  used tri-axial electrospinning to synthesize a tri-layer composite fiber with drug gradient 
distribution (Figure 4c1). The drug content of the fibers was gradually increased from outer 
layer to middle and inner layer, which comprised a system to stably release the drug in a zero-
order manner (Figure 4c2 and c3). 
In summary, co-axial/tri-axial electrospinning could provide feasibility for sustained and 
multistage drug release. More importantly, co-axial/tri-axial electrospinning widen the drug 
solution range to unspinnable fluids.[99-100] The limitations of co-axial/tri-axial electrospinning 
are mainly the complexity of the set-up configuration, and various working parameters need to 
be well controlled and the interfacial tension of inner and outer solutions need to be well 
adjusted. 
 
Table 3. Representative electrospun drug-loaded scaffolds via co-/tri-axial electrospinning and 
the associated highlights and applications. 
Materials Drugs Highlights Applications Ref. 




Drug release in two stages via pH-responsive 
manner; 
The ES100 shell dissolved in acid condition 
firstly (pH 1.0, 2.1% of drug release in 2 h); 
Released drug phospholipids further gradually 
released the drug at pH 7.0, which reached 79% 






loaded PEO and 
indomethacin 
Therapeutic and imaging agents were delivered 
simultaneously to the colon.  
Indomethacin had less than 10% of release at pH 











































































loaded PEO / 
DOX-loaded PEO 
The swelling and shrinking of thermal responsive 
nanogels (LCST 32 °C) located in the shell could 
create cavities as drug diffusion paths to control 









Delayed drug release; 
Rapid release of 40% of curcumin in 8 h and 
sustained release of 73% of drug over 10 d. 
Wound healing  [94] 
PEUU and 
PEEUU 







Sustained release of BMP-2 over 22 d; 
Fibers with thin shell thickness could release 




PCL Bevacizumab pH of core protein solution had influences on the 
resultant core-shell structure; 
With varying the pH, drugs can be released 
following a first-order kinetic (t1/2 of 11.4 d) or a 









Fibers with gradient distribution of drugs were 
prepared through tri-axial electrospinning; 








NGF/BSA Sustained release of NGF from conductive core-
shell fibers over 5 d, increased the percentage of 
neurite-bearing cells and median neurite length; 







PVP/Nisin Fabrication of fibers with three layers through tri-
axial electrospinning; 






Hyaluronic acid  Uniform distributed EGCG in PLGA shell was 
released in a stepwise manner for 28 d;  
Central-located hyaluronic acid was sustained 




PCL/Ag Hyaluronic acid/ 
PEO 
Complete release of Ag within 4 d; 
Initial rapid release of hyaluronic acid in 10 d 





ES100, Eudragit S100; Gd(DTPA), Gd(III) diethylenetriaminepentaacetate hydrate; LCST, lower 





































































urea; PEEUU, polyester ether urethane urea; AAV, recombinant adeno-associated viral; SF, silk fibroin; 
CS, chitosan; nHAP, nanohydroxyapatite; P(LLA-CL), poly(L-lactic acid-co-3-caprolactone); PANi, 
polyaniline; CA, cellulose acetate; PVP, polyvinylpyrrolidone; EGCG, epigallocatechin-3-O-gallate. 
 
Figure 4. (a) A diagram illustrating the influence of pH of drug solution on the fiber structure, 
drug distribution, and release kinetics when produced through co-axial electrospinning. 
Reproduced with permission;[98] Copyright 2017, Elsevier B.V. (b) Thermal responsive fibers 
using shell-located nanogels as valve were fabricated through co-axial electrospinning. 
Reproduced with permission;[47] Copyright 2015, John Wiley and Sons. (c) A study of tri-layer 
drug-loaded fibers through tri-axial electrospinning process. (1) Schematic illustration of the 





































































profile was achieved by the tri-layer drug-loaded fibers. Reproduced with permission;[99] 
Copyright, 2015, American Chemical Society. 
 
2.2.4 Emulsion electrospinning 
Sanders et al.[105] reported the first emulsion-electrospun fibrous structure in 2003. A two-phase 
W/O emulsion of BSA-water/poly (ethylene-covinyl acetate)-dichloromethane was used to 
enforce fiber formation through a single nozzle, generating a core-shell structure when the water 
droplets were stretched and solidified. Usually three phases comprise the spinnable emulsion: 
aqueous phase, oil phase and sometime surfactants, which enhance the stability of the W/O 
emulsion and influence the release behaviors (Figure 5a).[30a, 106] The emulsion stability, which 
is the essential factor determining the successful entrapment of biomolecules, can be maintained 
by choosing the appropriate surfactant, emulsification parameters and electrospinning 
parameters.[107] These factors synergically affect the successful spinning and the distribution of 
the bioactive molecules (either a core-shell structure or drug randomly embedded in matrix). 
Moreover, Yazgan et al.[108] found that relative humidity (RH%) and surfactant concentration 
had remarkable influences on the fiber structure, surface morphology, surface chemical 
composition and consequently the drug release kinetics in emulsion electrospinning. They 
proposed that optimized surfactant concentration with high RH% can render porous fiber 
surface, leading to rapid drug release. With increasing the concentration of surfactant Span 80, 
dense fiber surface can be formed, resulting in delayed drug release. In addition to the usually 
reported W/O emulsion, Basar et al.[109] synthesized PCL/ketoprofen(core)/gelatin(shell) fibers 
via electrospinning from an O/W emulsified suspension. The cross-linked gelatin was 
considered as a coating outside of the ketoprofen-loaded PCL fibers, and thus extended the drug 





































































affinity of natural gelation were combined for wound healing applications. Table 4 further 
summarizes the recent drug-loaded electrospun structures from emulsion electrospinning and 
describes the highlights.  
Compared to co-axial/tri-axial electrospinning, emulsion electrospinning is a simpler one-step 
process to form core-shell fibers without complicated spinneret configuration. Water-soluble 
and fragile biomolecules can also be well confined in the core section of fibers via emulsion 
electrospinning (Figure 5b). Their release kinetics were mainly determined by the diffusion 
and degradation of polymer shell as well. However, the addition of water phase into polymer 
solution could greatly affect the viscosity, surface tension and conductivity of original polymer 
solutions, therefore influence the fiber topography and the mechanical performances of the final 
drug-loaded fibrous scaffolds.[110]  
 
Figure 5. (a) An example of emulsion electrospinning process from W/O emulsions. 
Reproduced with permission;[111] Copyright 2014, Elsevier B.V. (b) Schematic illustration on 
the mechanism of the core-shell structure formation during the emulsion electrospinning 








































































Table 4. Representative electrospun DDS via emulsion electrospinning (core-shell structure) 
and the associated highlights and applications. 










The influences of polymer compositions, 
surfactants and drug characteristics on the release 
profiles were investigated; 
Slower and sustained drug release can be 












The higher the humidity, the more porous of the 
fiber surface leading faster drug release. 
With increasing the surfactant concentration, 
dense fiber surfaces could form, resulting in 








PCL (Oil phase) 
PCL/drug fibers were coated with a cross-linked 
gelatin through emulsion electrospinning of an 
unusual O/W system, resulting in sustained drug 









10% of release in 1 d, and then sustained release 





loaded hyaluronan  
Burst release of 26% of drug in 2 d and then 
sustained release over 40 d; 
The release pattern can be adjusted through 









Simultaneous delivery of multiple growth factors, 
such as FDGF, FGF, TGF-β1; 
Bust release in 5 d and following sustained 




PHBV, poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid); PS, polystyrene; PRP-derived, Platelet-
rich plasma- derived; FDGF, platelet-derived growth factor; FGF, fibroblast growth factor; TGF-β1, 








































































2.2.5 Secondary carrier electrospinning 
In addition to the fibrous structures as backbone, secondary carriers like micelles, liposomes, 
nanogels, nanoparticles and nanotubes, can be physically entrapped into the fibers to form nano-
in-nano or nano-in-micro structures for multi-purpose drug delivery. In theory, multiple drug-
loaded particles could be delivered simultaneously resulting in multi-drug release. 
 
 
Table 5 lists the recent studies on electrospun DDS containing secondary carriers, and their 
highlights and applications are summarized. Technically, drug-loaded secondary carriers were 
dispersed into the polymer solution (with or without drugs) prior to blend electrospinning, and 
a co-delivery of multiple drugs was achievable according to specific requirements. The 
hierarchical drug delivery systems were appealing owing to the multi-barrier function, which 
can not only protect bioactive molecules from harsh environment and degradative conditions, 
but also allow sequential release of drugs under appropriate triggers.[116] In addition, prolonged 
drug release was feasibly achieved due to the added physical barriers or strong interactions 
between drugs and carriers. For instance, Chandrawati et al.[117]  successfully embedded β-
glucuronidase-loaded liposomes within PVA fibers by blend electrospinning for enzyme 
prodrug therapy (Figure 6a). They reported that enzyme-loaded liposomes remained intact 
within PVA fibers and the release of enzyme can be mediated via phase transition temperature 
of the liposomes for at least seven weeks. This release period is much longer than the normal 
active period of β-glucuronidase in biomaterials (maximum 7 days). In a study of Luo et al.,[34b] 
camptothecin was initially loaded into promicelles (PMCPT) and subsequently embedded in 





































































tumor site, PMCPT were sustained released and self-assembled into folate-targeted and 
glutathione (GSH)-sensitive micelles, which were taken-up by the tumor cells continuously 
(Figure 6b). By adjusting the composition ratio of polymer blends, the constant release of PMs 
can be prolonged over 30 days, which significantly enhance the anti-tumor efficacy. Xue et 
al.[118] incorporated metronidazole (MNA)-loaded halloysite clay nanotubes (HNT) into 
PCL/gelatin fibers through blend electrospinning. A combination of free drugs and drug-doped 
HNT in the fiber resulted in a burst release in 4 days and sustained release up to 20 days, 
providing sufficient antibacterial effect in the GTR/GBR implant membranes. 
 
Table 5. Representative electrospun DDS via secondary-carrier electrospinning and the 
associated highlights and applications. 
Materials Drug-loaded 
carrier 
Highlights Applications Ref. 
EL55 Peptide-loaded 
PEC nano-carriers 
pH-responsive nano-in-nano system for multi-
stage drug release; 
Nanocarriers release at pH 6 and peptides release 







β-glu release was mediated via phase transition 
temperature of the liposomes； 
The active enzyme release was extended from 7 













Sustained release of PMCPT over 30 d; 
Self-assembled drug-loaded micelles on the 
tumor site were up-taken into tumor cells via FA-










Burst release and following sustained release of 









































































MSNs caped with 
CaCO3 gates 
The lower the pH, the higher amount of CaCO3 
was dissolved, leading higher amount of DOX 
release from MSNs; 
Sustained DOX release up to 40 d. 
Cancer therapy [55a] 
EL55, Eudragit L100−55; PEC, polyelectrolyte complex; β -glu, β -glucuronidase; PMCPT, 
camptothecin containing promicelle; MSNs, mesoporous bioactive glass nanospheres. 
 
Figure 6. (a) Enzyme-loaded liposomes were encapsulated into PVA fibers through secondary 
carrier electrospinning and the drug release can be mediated through the thermal phase 
transition of liposomes. Reproduced with permission;[117] Copyright 2017, John Wiley and Sons. 
(b) Anticancer drug-loaded promicelles were embedded into blend polymer fibers through 
secondary carrier electrospinning. Reproduced with permission;[34b] Copyright 2017, Elsevier 
B.V. 
 
2.2.6 Combination of multiple techniques  
As an extension to secondary electrospinning, the combination of two or three drug-loading 





































































function in the complex in vivo environment and cannot meet the increasing demand to deliver 
and precisely release the multi-drugs in a multi-stage or sequential manner. Table 6 gives 
several examples that combine two or more electrospinning approaches to achieve multi-drug 
delivery.  
 
Cheng et al.[29d] functionalized the ginsenoside-Rg3-loaded fibrous scaffolds with RGD and 
bFGF through pDA coating chemistry. Results indicated that surface functionalization feasibly 
promoted the cellular activity without impairing the original drug loading and release behavior. 
Man et al.[63] combined co-axial electrospinning with surface functionalization to deliver two 
biomolecules aiming for chondrogenic differentiation. The chondrogenic growth factor rhTGF-
b1, which was initially entrapped in the core of PCL fibers, were gradually released up to 21 
days. In addition, the BMSC-specific affinity peptide E7, which was subsequently conjugated 
onto the PCL fibers surface via covalent bonding, synchronously promoted the BMSCs 
adhesion and proliferation. The drug carriers were also immobilized on the fibers surface by 
Monteiro et al.[119] through covalent bonding. Thiol group was firstly inserted to bond with the 
amine group of chitosan fibers, and the gentamicin-loaded liposomes were then immobilized 
onto the modified chitosan fibers via maleimide reaction to achieve steady released gentamicin 
for antibacterial applications. The immobilization of drug-encapsulated liposomes onto the 
fiber surface could inhibit the drug denaturation, and avoid the toxicity brought by high dose of 
drug.  
Li et al.[65] fabricated PCL-co-PEG scaffolds with dual-drug release capability in two stages. 
Dexamethasone (DEX) and BMP-2 encapsulated bovine serum albumin (BSA) nanoparticles 





































































DEX was finished in the first 8 days and the BMP-2, which was protected by two barriers, were 
released in a sustained manner up to 35 days. This time-programmed dual-drug release 
manifested the highest bone repair efficiency. Song et al.[120] fabricated a nano-in-nano structure 
by encapsulating vancomycin-loaded gelatin nanospheres into the silk fibroin membranes 
through single-nozzle or co-axial electrospinning. The drug-loaded nanoparticles were further 
entrapped within the core section of electrospun fibers, enabling an extended drug release up to 
14 days. Similarly, Yang et al.[121] successfully confined DOX-loaded FA-PCL-PEG copolymer 
micelles in cross-linked gelatin fibers through co-axial electrospinning. A step-wise release of 
initial active micelles and subsequent DOX was achieved by this micelle-in-nanofiber device. 
Modified tri-axial electrospinning was also combined with drug-loaded lipids to constitute a 
multilayer and smart drug carrier system for oral drug delivery.[16b] In a study of Yang et al.[16b], 
diclofenac sodium/phosphatidyl choline (DS/PL) lipids were entrapped in the core of ES100 
fibers through tri-axial electrospinning to achieve a pH-stimuli triggered and sustained drug 
release. This proof-of concept research explored the influence of spinnability of outer-middle-
inner solutions on the final fiber structures, and greatly enlarged the selection pool of raw 
materials. All types of liquid phases could be processed through this modified tri-axial 
electrospinning, including small molecule solutions and diluted polymer solutions, which were 
un-spinnable in the traditional electrospinning.  
In addition to the polymer nanospheres, mesoporous bioactive glass nanoparticles (MBNs) 
were also regarded as superior drug carriers to prolong the drug release due to the high surface 
volume ratio for absorbing biomolecules. Kang et al.[122] incorporated fibroblast growth factor 
2 (FGF2) and fibroblast growth factor 18 (FGF18)-loaded MBNs into the hollow core of PCL 
fibers through co-axial electrospinning. FGF2 was designed to dominantly release in the earlier 





































































osteogenesis. By adjusting the single (PCL shell) or double layer (PCL shell and MBNs) of 
barriers, the sustained release patterns can be manipulated as desired.  
The versatility of electrospun DDS also enable the production of complex and multi-functional 
implants possible. Liu et al.[62] fabricated a uniformed mixed membrane consisting of 
hyaluronic acid fibers and collagen fibers by simultaneously running two electrospinning 
apparatuses. EGF, pDFG-loaded gelatin NPs, VEGF-loaded gelatin NPs and bFGF were 
dispersed into collagen fibers and hyaluronic acid fibers through blend electrospinning, 
respectively, forming a composite scaffold with potential to deliver four growth factors in a 
stage-wise manner for 30 days. The earlier released bFGF and EGF were responsible for the 
epithelialization and vasculature sprouting and the delayed release of pDFG and VEFG were 
aiming for blood vessels maturation. 
 
Table 6. Representative electrospun DDS via combinational-drug incorporation approaches 
and the associated highlights and applications. 
Materials Drugs Highlights Applications Ref. 
PLGA Rg3,  
PEG-NH2,  
RGD and bFGF 
Combination of blend electrospinning and 
surface functionalization; 
Sustained release of Rg3 for 40 d;  
Combination of the wound healing and inhibition 
of hypertrophic scars formation. 











Combination of co-axial electrospinning and 
covalent surface functionalization; 
Dual drug release: burst release of rhTGF-β1 in 5 
d, and sustained release for 22 d; E7 on the PCL 










Combination of drug-loaded BSA nanoparticles 











































































Dual-drug release in a sequential manner: initial 
dexamethasone release in 8 d and sustained 








Combination of drug-loaded MBNs, blend and 
co-axial electrospinning; 
Dual growth factors up to 65 d in sequential 
manner: fast release of FGF2 and sustained 











and PVA blend 
(core) 
Combination of drug-loaded micellar system 
with co-axial electrospinning. 
Burst release of DOX in 20 h and more than 80% 
of DOX was released in 288 h.  
Delayed release of DOX was achieved by gelatin 
shell and micelles. 




Gentamicin-loaded liposomes were covalently 
immobilized onto chitosan fiber surface;  








gelatin NPs;  
bFGF and EGF 
Combination of drug-loaded gelatin NPs with 
blend electrospinning; 
Programmed, sequential release of four growth 
factors (burst release of bFGF and EGF; sustained 
release of VEGF and PDGF-BB) up to 1 month. 
Chronic 
wound Healing  
[62] 




Dual-drug release through micelles with blend 
electrospinning; Burst release of paclitaxel (~ 
60%) and the prolonged release of Brefeldin A (~ 
20%) in the first 96 h. 
Cancer therapy [123] 
Rg3, (20R)-Ginsenoside Rg3; rhTGF-β1, recombinant human transforming growth factor-b1; BMSC-
E7, Bone marrow-derived stem cells specific affinity peptide E7; FGF2, fibroblast growth factor 2; 
FGF18, fibroblast growth factor 18; FA, folate; PDGF-BB, platelet-derived growth factor BB. 
 
2.3 Drug release kinetics 
When released from fibers, drugs go through a cascade of partitioning and diffusion processes 
within fibers and following dissolution in medium.[6, 124] In non-degradable fibers, the drug 





































































of the matrix and the drug dissolution rate in the medium, since the average drug diffusion path 
stays constant. However, in degradable polymer fibers, the polymer degradation rate also plays 
a key role, because the average diffusion path changes with time.[125] More specifically, during 
the fabrication of electrospun DDS, many factors relating to construct, matrix material and 
drugs can affect the above two-way diffusive process, and thus, influencing the drug release 
behavior (Table 7). Materials, drugs and their interactions will be particular highlighted in the 
following sections of this review. 
Table 7. Possible factors that contribute to the drug release mechanisms [7b, 80, 124-126]. 
Aspect of Construct  Aspect of Material  Aspect of Drug  
Geometry Composition Drug loading 
Dimension Molecule weight Drug state 
Porosity Crystallinity Drug molecule weight 
Pore size Degradation rate Drug-solubility in medium 
Fiber diameter Swelling ability  
 Drug-polymer interactions 
 Drug distribution within fibers 
 
2.3.1 Influence of materials 
The intrinsic nature of the drug carrier initially determines the drug release duration. When 
drugs were encapsulated within water-soluble polymers, such as PVA and PVP, they usually 
achieve full drug release within few minutes or hours.[10a, 11b] The release rate will be accelerated 
in electrospun fibers owing to the enhanced solubility.[10a] The hydrophilicity of natural drug 
carriers can increase the medium absorption, and thus, enhancing the drug diffusion, leading to 
rapid drug release. Cross-linking is the main strategy adopted to prolong the drug release in 
natural polymer fibers.[127] On the contrary, a hydrophobic polymer matrix with varying 
degradation rate can extend the release duration to days even months.[34a, 91-92] The exact release 





































































biopolymers.[128] Table 8 gives few examples of drug release duration of electrospun DDS 
through blend electrospinning. 
Moreover, the feasible blending of polymers provides facile approach to regulate the drug 
release duration aiming for diverse applications.[34a] In case of stimuli-responsive materials, 
DDSs usually show instant drug release upon sensing the stimuli and sustained release in 
absence of the stimuli.[41] Nevertheless, when the drugs were located on the surface or near 
surface vicinity without strong linking, the release duration may show little relevance to the 
materials nature.[129]   
 
Table 8. Few examples of drug release duration of electrospun DDS through blend 
electrospinning. 




100% within 60 s ~240 s 







100% within < 1 min 
100% within ~ 120 min 
[130] 
[11b] 
Fish gelatin - 100% within 4 min [12] 
PCL/gelatin 70 ~ 90 (PCL) 22 d ~ 32d [31a] 
PLLA/PEG PLLA 50, PEG 2 8 ~14 d [34a] 
PLLA/PEG 100 < 50% over 90 d [92] 
PLA 78 10% ~ 80% over 84 d [91] 
PCL In-situ synthesis < 15% over 56 d [88] 
Poly-urethane In-situ synthesis < 60% over 91 d [81] 
 
2.3.2 Influence of drugs and drugpolymer interactions 
Drug-type (molecule weight and solubility) and drug loading ratio are two aspects that strongly 
influence the release kinetics. Pattama et al.[131] thoroughly investigated the drug release 





































































fibers. It was observed that sodium salicylate, which had low molecule weight (160.1 g mol-1) 
and high water solubility, reached near 100% of release within few minutes. However, only less 
than 40% of water insoluble indomethacin (357.8 g mol-1) was released over 1400 min. The 
different release tendency was explained by the faster leaching out of matrix in case of low 
molecule weight drugs. In the early studies, Zeng et al.[80] studied the drug release behavior of 
paclitaxel, doxorubicin hydrochloride and doxorubicin base from PLLA fibers. Both PLA fibers 
containing paclitaxel and doxorubicin base showed constant zero-order release, which was 
proportional to the polymer degradation, whereas doxorubicin hydrochloride-loaded fibers 
showed rapid drug release, which was irrelevant to the PLA degradation. It was concluded that 
stable and constant drug release can be acquired when majority of the drugs were embedded 
inside of the fibers by selecting proper lipophilic polymer/lipophilic drug pair and hydrophilic 
polymer/hydrophilic drug pair. 
Potrč et al.[129] entrapped hydrophilic ibuprofen and hydrophobic carvedilol into PCL fibers, 
respectively, with loading ratios ranging from 10% to 60%. The dissolution tests indicated that 
all systems exhibited a burst drug release following with a plateau. All fibers in PCL/ibuprofen 
group reached near 100% of release within 6 h; however, only 6080% of drugs were released 
within 6 h in PCL/carvedilol group. In each group, higher drug loading practically delayed the 
drug release rate to some extent. They also pointed that the delayed release of carvedilol could 
be explained by the high molecular weight of carvedilol and the stronger 
hydrophobichydrophobic interactions between matrix and drugs. Similarly, in the study of 
Roman et al.[91], the sustainable release of paclitaxel from PLA fibers were notably delayed by 
the high drug loading ratio. Over 60% of paclitaxel was released over 84 days in PLA fibers 
with a drug loading ratio of 0.25%, vs 30% to PLA fibers with a ratio of 0.58%. However, 





































































and chlorotetracycline were encapsulated into electrospun PDLLA fibers, respectively. 
Increasing the ratio of tetracycline highly accelerated the drug release, whereas increasing the 
ratio of chlorotetracycline significantly decreased the drug release rate. The controversial 
results could be due to the different polymer/drug/solvent interactions occurred. 
Above studies relevant to polymerdrug interactions were all conducted in drug-laden fibers 
through blend electrospinning, from which the spontaneous drug distributions completely 
depend on the intrinsic interactions between polymers and drugs. However, through multiple 
modified drug incorporation techniques, drug distributions could be practically manipulated, 
generating programmable drug release behavior.    
 
2.3.3 Influence of drug incorporation techniques 
As thoroughly discussed in former sections, drug distributions within matrix, which directly 
affect the drug diffusion paths, can be feasibly manipulated through different incorporation 




Table 9 further comparatively describe the advantages, limitations and possible drug release 











































































Table 9. Advantages, limitations and possible drug release profiles of different drug 
incorporation techniques. 
Techniques Advantages Limitations Release Trends Ref. 
Surface 
Immobilization 
Avoiding harmful solvents 
for biomolecules; 
Maintenance of the original 
physical or degradation 
properties of matrix; 
 
Cross-linker necessary 
for long term release; 
Rapid and burst 
release in case of 
weak bonding; 
Sustained release in 







Simple one-step approach; 
 
Possible denaturation of 
drugs in the harsh 
organic solvent; 













































































Sustained release in 





Ideal for core-shell structure; 
Feasible entrapment of 
water-soluble or fragile 
drugs within the core of 
fibers; 
Unspinnable drug solution 
can be used; 





interactions  may cause 
failure in core-shell 
structure; 
Rapid and burst 
release in case of 
hydrophilic and fast-
degradable shell; 
Sustained release in 








Single one-step approach for 
core-shell structure;  
 
Emulsion stability need 
to be well adjusted 
through surfactants and 
other emulsification 
parameters; 









Ideal for multi-drug release; 














Overall, by choosing the appropriate encapsulation approaches, various drugs can be either 
attached onto the surface, embedded in the surface vicinity, uniformly distributed throughout 
the whole fibers, or fully confined within the core section of fibers, resulting in rapid, sustained 
or zero-order drug release profiles. Therefore, when choosing ideal drug release platforms for 





































































composition and the encapsulation technique, which could synergically affect the drug release 
patterns and thus the treatment efficacy. 
 
3. Applications in Biomedical Fields 
As discussed above, numerous electrospun scaffolds containing diverse active ingredients can 
be easily produced through selecting proper materials and approaches. The resultant drug-laden 
architectures offer massive variations on physical topography, drug loading degree, drug release 
behavior, and thus, ultimately lead to therapeutic effects, which potentially meet multiple 
clinical needs. In the current section, the therapeutic outcomes of drug-containing electrospun 
DDS in some biomedical fields, with a particular focus on tissue engineering and cancer therapy, 
will be thoroughly discussed below. 
 
 
3.1 Simple Drug Delivery Systems 
Due to the high drug loading and high encapsulation efficiency, implantable drug-eluting 
electrospun fibers have intrinsic advantages over the conventional small-scale drug vehicles as 
novel drug administration methods through oral, transdermal or ocular routes.[8, 133] The 
following sections will summarize the recent endeavors made on these fields and highlight the 
superiority of electrospun drug formulations. 
 
3.1.1 Oral drug delivery 
Electrospinning technique is able to produce highly porous and fibrous membrane consisting 
of continuous nanofibers. The highly interconnected porous structure of electrospun fibers 





































































the hydrophilic polymers. And the nano-size dimension indicates well dispersible drug particles 
in polymer matrix, causing a great increase of drug solubility.[7a] These features enable the 
electrospun fibers good candidates for FDDDS of bitter drugs in oral cavity. Samprasit et al.[11b] 
explored the potential of electrospun PVP/cyclodextrin (CD) fibers to deliver meloxicam (MX) 
in oral cavity. This study demonstrated faster disintegration of electrospun PVP/CD fibers than 
the MX powder, commercial tablet and casting films. The optimized and taste-masked 
formulations were non-cytotoxic, physical stable for 6 months in storage condition and all of 
them disintegrated within one minute in simulated moisture environments of oral cavity (Figure 
8a). Li et al.[10a] investigated the performances of drug-loaded PVA fibers as FDDDS 
formulation and reported that PVA/caffeine and PVA/riboflavin fibrous mats got wetted within 
4.5s and started disintegration within 1.5s. 
Oral formulations have also been exploited for sustained drug release via the sublingual route 
rather than FDDDS. It is an invasive administration and advantageous for the drugs that need 
to be continuously taken-up into the blood circulation. Sharma et al.[15] fabricated an anti-
diabetic patch by electrospinning of insulin-loaded PVA/sodium alginate (NaAlg) composite 
fibers, from which the insulin was supposed to be released sublingually and absorbed through 
oral mucosa. The in vivo experiments conducted by applying the patch below the tongue of a 
diabetic rat. Resultant blood glucose concentration of the diabetic male Wistar rats was 
significantly reduced and the effect lasted for 10 h. 
In addition to oromucosal delivery system, electrospun membrane can be further used as oral 
formulations to achieve colon-targeted release. Yang et al.[16b] confined lecithin diclofenac 
sodium (phospholipids PL-DS) within ES100 fibers through co-axial electrospinning to create 
a pH-sensitive drug carrier (Figure 8b1, 2). The outer ES100 layer could protect the central-





































































environments when the drug carriers reach the colon. Subsequently, partial DS was freed when 
the DS-loaded lipids were converted to sub-micron sized particles and more DS was 
continuously released from the lipid particles (Figure 8b3). The ex-vivo permeation tests 
indicated highly enhanced colonic membrane permeation ability of fiber dosage compared to 
free drug. In another study, Jin et al.[44] loaded Gd(DTPA) and indomethacin within the core 
section of ES100 fibers through co-axial electrospinning to colon-targeted deliver the magnetic 
resonance contrast agent  for imaging diagnosis and therapeutic agents simultaneously (Figure 
8c).  
  
Figure 8. (a) Images of meloxicam-loaded PVP/CD fibrous mats with different compositions 
as FDDS in the disintegration tests. Reproduced with permission;[11b] Copyright 2015, Elsevier 
B.V. (b) Oral formulation of lecithin diclofenac sodium/ES100 core-shell fibers for colon-
targeted drug delivery. (1) SEM and (2) TEM images of the produced core-shell fibers. (3) The 
proposed drug release mechanism in responsive to neutral and acid conditions. Reproduced 
with permission;[16b] Copyright 2016, American Chemical Society. (c) Core-shell fibers to 





































































therapeutic agents simultaneously. Reproduced with permission;[44] Copyright 2016, Elsevier 
B.V. 
 
3.1.2 Transdermal drug delivery  
Transdermal drug delivery represents the strategy of drug administration through skin, which 
is the largest organ in human body.[134] It has several advantages over hypodermic injections, 
such as easy accessibility due to the high surface area of skin, less invasive operations required 
and avoidable hepatic first-pass metabolism.[135] The drugs can be either absorbed through skin 
barrier into subcutaneous tissue and systematically taken-up into the blood circle, and then the 
whole body, or remained locally to treat skin disorders, such as dermatitis or skin cancer, i.e. 
topical drug delivery.[135] As the outermost layer of skin, stratum corneum is responsible for the 
poor drug absorption and only small quantity of drugs can be penetrated into skin. By applying 
appropriate drug carriers on the skin, long term drug release can be simply achieved.[134] 
Conventionally, emulsions, creams, gels and transdermal patches are all ideal drug carriers for 
transdermal drug release.[18b] Owing to the capability of high drug loading and encapsulation 
efficiency of electrospinning technique, drug-loaded electrospun membranes are considered as 
superior options as transdermal patches.  
Song et al.[17b] successfully embedded daidzein-loaded lipids into electrospun PLGA nanofibers 
as transdermal patches to address the problems associated with poor oral absorption and limited 
bioavailability of daidzine for treating cardiovascular and cerebrovascular disease. A skin 
permeation enhancer, Azone, was also blended into PLGA matrix to increase the drug diffusion 
rate by interacting with structured lipids of the stratum corneum. In vitro drug release and skin 
permeation studies showed ~3.8 times higher amount of fiber-released daidzein penetrated skin 





































































observed in case of composite fibers than daidzein-loaded lipids in the long-term period and no 
obvious skin irritation was observed. More studies have explored the potential of electrospun 
fibers from diverse polymers as transdermal patches, such as PVP,[21] PVA/chitosan,[136] 
PU/cellulose,[19] and PVA/Alginate.[22b] 
 
3.1.3 Ocular drug delivery 
Electrospun patch has been also investigated to deliver drugs into eyes for ocular surface repair. 
Most common clinical substrate for ocular surface repair is human amniotic membrane owing 
to its biocompatibility, anti-inflammation efficacy and angiogenesis ability.[137] However, it 
also has several disadvantages, such as poor mechanical strength, semitransparent appearance, 
difficulty of handling and the potential risk of disease transmission,[138] and therefore, 
alternative choices should be further explored. Compared to bulk material, electrospun patches 
with micro/nano- size fiber dimensions and high surface area were considered advantageous in 
topical application or treating the anterior segment eye diseases. Bhattarai et al.[139] fabricated 
two different dexamethasone-loaded PLA/PVA patches as ophthalmic inserts through either 
solvent casting or electrospinning method, and further compared the drug release behavior. 
Results indicated that 90% of the drug was released from the electrospun inserts over 40 h and 
only 24 h from the solvent-casting inserts. Compared to solvent-casting inserts, electrospun 
inserts showed more consistent and predictable drug release. In another study of Baskakova et 
al.[140], acyclovir, cyanocobalamin and ciprofloxacin were simultaneously incorporated into 
PCL fibers to fabricate fibrous matrices as intravitreal implants. Drug release using an in vitro 
eye model showed that the drug residence time (half-life) was extended to 6 days, which was 
much greater than the small molecule drug solutions, suggesting that the proposed matrices can 





































































a VEGF neutralizing antibody, into the core area in PCL fibers through co-axial electrospinning 
to treat age related macular degeneration. This fibrous solid formulation highly prolonged the 
drug release period over two months, and therefore, reduced the administration frequency and 
avoided the invasive injection in the eyes.  
 
 
3.2 Tissue Engineering 
Tissue engineering represents a multidisciplinary field integrating the materials, chemistry and 
biological science. Aiming for in-situ tissue regeneration or organ restoration, cells are 
supposed to attach, proliferate and differentiate under the support of the 3D scaffold,s which 
will degrade gradually in the meanwhile.[141] Another essential link in this strategy is suitable 
biochemical and physicochemical factors that are molecularly affect or guide the cellular 
behaviors. It is well-known that electrospun scaffolds are widely applied as scaffolds for tissue 
regeneration owing to the excellent physical resemblance to ECM. Moreover, increasing studies 
focus on applications of active ingredients-loaded fibrous scaffolds in pursuit of improved 
therapeutic outcomes. Their achievements made on regeneration or restoration of multiple 
organs, such as skin, bone, cartilage, muscle, tendon, heart, nerve and blood vessels, are 
discussed in this section.   
 
3.2.1 Wound healing and skin tissue regeneration  
Wound healing is a dynamic and interactive process involving dermal cells (e.g., fibroblasts, 
endothelial cells), growth factors (e.g., EGF, FGF-2, and VEGF), cytokines, etc. Four periods 





































































in this process.[142] As described above, the high porosity and surface area enable electrospun 
structure an optimal candidate to fulfill the mission of conventional wound dressings, such as 
being permeable to moisture and oxygen, protecting the wound from microbes and mechanical 
irritation and allowing the exudate removal.[143] Additionally, the high resemblance to ECM 
and feasibility for multifunctionlization make electrospun drug-loaded scaffolds prospective in 
treating skin trauma and disorders, especially for some chronic skin diseases which have no 
clinical cures yet.   
Antibacterial property is the primary function required for a wound dressing material and it can 
be easily achieved by incorporating antibiotics,[90, 144] antibacterial peptide motif[78] and 
antibacterial nanoparticles,[33c] into electrospun membranes. For instance, tetracycline 
hydrochloride was loaded into PCL/cellulose acetate/dextran and PVA/chitosan composite 
membranes to facilitate wound healing, respectively.[144] The obtained membranes were proved 
to be biocompatible and bioactive, and effectively antibiotic against bacterial. An antimicrobial 
peptide motif (Cys-KR12) was immobilized onto electrospun silk fibroin nanofiber surface 
through EDC/NHS and thiol-maleimide click chemistry by Song et al.[78] In addition to the 
antibacterial efficacy, the immobilized Cys-KR12 further promoted the proliferation of 
keratinocytes and fibroblasts and the differentiation of keratinocytes, and also inhibited the 
inflammatory cytokine expression.  
Apart from the feasible implementation in acute infections of wound sites, electrospun scaffolds 
are able to sustainably release therapeutic agents and simultaneously support in-situ tissue 
regeneration for curing chronic wound diseases, such as diabetic wound diseases.[62, 103, 145] 
Various drug-loaded scaffolds were designed to improve the poor angiogenesis and delayed 
wound closure in diabetic wounds associated with high blood glucose level, and therefore to 





































































(VEGF, bFGF, PDGF and EGF) into collagen/hyaluronic acid composite scaffolds to rapidly 
increase the blood vessels formation and further allow fast integration with surrounding tissues. 
An examination on in vivo streptozotocin (STZ)-induced diabetic rats model confirmed 
increased vessel density and lumen area, elevated collagen deposition and subsequent 
accelerated wound closure rate. Other angiogenic agents, such as epigallocatechin-3-O-gallate 
and desferrioxamine, were also loaded into hyaluronic acid/PLGA and PVA/chitosan scaffolds, 
respectively, to dramatically increase the neovascularization and collagen deposition, and thus, 
promote the diabetic wound healing.[103, 146] 
Ren et al.[145b] developed a composite scaffold consisting of both beneficial micro/nano 
structural cues and chemical active agents to create a synergistic microenvironment for rapid 
diabetic wound healing (Figure 9). It was observed that nanopores enhanced the protein 
adsorption, and thus, the cellular adhesion and proliferation, and the aligned fibers favorably 
regulated the endothelial cellular angiogenesis differentiation. 0%, 5%, 10% and 15% of 
dimethyloxalylglycine (DMOG)-loaded MSNs (PL, 5 DS-PL, 10 DS-PL and 15 DS-PL) were 
embedded into aligned PLLA fibers with nanopores on the surface for sustained release of both 
DMOG and Si ions, which both have positive effects on the angiogenesis of endothelial cells. 
As shown in Figure 9a, drug-loaded MSNs were uniformly distributed throughout the aligned 
PLLA fibers with interconnected nanopores and varying ratios of DMOG and Si ions can be 
stably released over 360 h (Figure 9b,c). An in vivo study of placing the 10% of DMOG-
MSNs/PLLA fiber meshes onto wound regions in the diabetic mice proved that drug-loaded 
fiber meshes significantly enhanced the wound healing ratios (97%) after 15 days of treatment, 






































































Figure 9. (a) SEM images of the aligned porous electrospun membranes with increasing drug 
ratios. The corresponding TEM image inserted in each SEM images. (b) DMOG and (c) Si ion 
release profiles. (d) Overview of the size change of the large excision wounds made in the dorsal 
skin of diabetic mice (control, PL and 10 DS-PL) at 0, 7, 11, 13, 15 day post-surgery. (e) Traces 
of wound bed closure for each treatment group in vivo. (f) Statistical analysis of wound area. 
*P < 0.05, **P < 0.01, ***P < 0.001. Reproduced with permission;[145b] Copyright 2018, 
Elsevier B.V.  
 
Studies focusing on the other aspects of wound healing were also reported. Cheng et al.[29d] 
encapsulated a bioactive drug 20(R)-ginsenoside RG3 onto PLGA fibers through pDA coating, 
and then further immobilized bFGF onto fibers surfaces to inhibit the formation of hypertrophic 





































































fabricate antibacterial PCL membranes, which reduced the inflammation and promoted the 
wound healing in vivo. This convenient handy device holds great potential to meet the clinical 
needs in emergency medical transport, hospitals, or first aids at home. 
 
3.2.2 Musculoskeletal tissue regeneration 
Musculoskeletal tissues play a vital role to offer physical support and allow stable movement 
of human body and could extend to bone, skeletal muscle, and connective tissues, e.g. tendon, 
cartilage and ligament.[148] The disease and injury related to musculoskeletal tissues can be 
acute bone or muscle trauma, or chronic osteoarthritis, rheumatoid arthritis and degenerative 
disc disease.[148a] Large bone defects and severe injuries in muscles and connective tissues (i.e. 
cartilage, tendon and ligament) have low intrinsic healing capacity due to the lack of 
vascularization and poor blood supply.[149] Tissue engineering appeared as an innovative and 
promising strategy to endow the in-situ regeneration ability to these severe defect sites. The 
produced fibrous scaffolds are usually applied in musculoskeletal tissue regeneration in two 
approaches. Firstly, 3D structural scaffolds are implanted to maintain the geometrical integrity 
of the target tissue and provide the necessary support for cells to attach, proliferate and 
differentiate in the meanwhile.[150] Another method is preparing and utilizing occlusive 
membranes for providing space maintenance, covering the diseased area, promoting the 
recruitment and growth of osteogenic cells and blocking the migration of competing soft tissue 
cells from overlying mucosa.[77, 151] 
Incorporation of small molecules or single growth factor is one of the simplest way to load 
therapeutics into scaffolds for better performances. For better skeletal muscle regeneration, Liu 
et al.[152] coated PCL fibers with mussel-inspired poly-norepinephrine (pNE), a catecholamine 





































































enriched with catechol groups that attract primary amine or thiol-based biomolecules. Their 
study revealed that fiber meshes with thinner fiber diameter could be more effectively 
functionalized by pNE, and thus had higher muscle cell proliferation and adhesion and 
treatment efficacy for repairing impaired musculus rectus abdominis in a rat muscle injury 
model. In the study of Pauly et al.,[153] connective tissue growth factor (CTGF) was conjugated 
onto longitudinally aligned PCL fiber bundles to mimic the hierarchical structures of native 
human anterior cruciate ligament (ACL) for ACL regeneration. CTGF was sustainably released 
over 2 weeks, evidenced by an ELISA assay. Elongated cells along the longitudinal axis fully 
covered the fiber bundles after 7 days, and significant collagen deposition specific for ligament 
tissue was observed on CFGF-loaded fiber bundles after 21 days of in vitro cell culture, which 
was further confirmed by the in vivo subcutaneous implantation tests. For repairing cartilage 
defects in osteochondral injuries, Liu et al.[115] constructed platelet-rich plasma (PRP)-loaded 
PCL scaffolds to obtain co-delivery of multiple therapeutic agents. Abundance of growth 
factors derived from PRP, such as PDGF, TGF-b and IGF, were simultaneously released from 
the porous scaffolds over 30 days. Highly enhanced gene expression of collagen-II, aggrecan 
and SOX9 suggested beneficial chondrogenesis of BMSCs when cultured on PRP containing 
scaffolds. The in vivo healing efficacy was evaluated by implanting the scaffolds in a New 
Zealand rabbit model with full-thickness cartilage and subchondral bone defect. The cartilage 
defect was nearly filled with regenerated tissues with glossy and normal articular surface 12 
weeks after the surgery, while there was still a gap to be filled in the pure PCL scaffolds group. 
Tendon tissues mainly constituting of parallel collagen fibrils work as an intermediate 
connector between the bone and muscle to achieve stress transfer and joint stability.[154] 
Although aligned fibers have been reported to promote tenogenesis, it is not enough for teno-





































































(TSA), an histone deacetylases inhibitor, into aligned PLLA nanofibers to commit teno-
differentiation of stem cells for tendon tissue regeneration. Comparative in vitro tendon 
stem/progenitor cell culture studies on random fibers and pure polymer fibers, displayed highly 
elevated tendon-associated genes expression and collagen accumulation in groups with both 
aligned topography and TSA entrapment, which could be further verified by the enhanced 
neotendon formation in an in vivo Achilles tendon repair model. Adhesion formation associated 
with fibroblast adhesion and proliferation is the major clinical complication in tendon healing 
after tendon surgery, and it could severely affect the joint movement. To eliminate the risk of 
adhesion formation, Zhao et al.[114] prepared core-shell hyaluronan/PLLA fibrous scaffolds 
with mitomycin-C (MMC) embedded in the core area of fibers, since MMC was reported to 
prevent the adhesion formation without impairing the tendon healing process (Figure 10a). The 
obtained fibrous membrane was designed to act as a physical barrier to mediate apoptotic gene 
expression and inhibit collagen expression in adhesion tissues. In vitro drug release study 
showed sustained release of MMC up to 40 days (Figure 10b), which efficiently inhibited the 
survival, adhesion and proliferation of fibroblasts. The healing efficacy were evaluated in both 
animal models of rabbit flexor digitorum profundus (FDP) tendon and rat Achilles tendon 
(Figure 10c, d). Severe adhesions were observed in the untreated control group in both models, 
and groups treated with PLLA-only membranes generated small bundles of fibrous tissues, 
connecting the tendon with surrounding tissues. Very little adhesion was observed in the 
repaired tendon and the peritendinous tissue when treated with MMC-loaded PLLA membranes 
in both models. This gross observation was further confirmed by the following histological 
analysis (Figure 10c2, d2). Consequently, the adhesion scores and grades for the histological 
tendon adhesions of the drug-loaded groups were both significantly lower than the control and 





































































further explained by the identification of the up-regulation of apoptotic protein Bax expression 
and down-regulation of proteins Bcl2, collage I, collagen III and α-SMA during the healing 
process with minimum adhesion formations. Overall, the proposed scaffolds were considered 
to be highly prospective as anti-adhesion materials in tendon tissue regeneration.  
 
Figure 10. (a) Cumulative release and (b) daily release of MMC from electrospun PLLA-MMC 
fibers (1 and 4% of MMC in MMC1 and MMC2). (c1 and d1) Gross evaluation of the rabbit 
FDP tendon and rat Achilles tendon model in control, PLLA and PLLA-MMC2 groups. HE (c2 
and c3) and Masson (d2 and d3) staining of control, PLLA and PLLA-MMC2 groups. T, 
tendon; M, membrane. 21 days after surgery, tendon repair and peritendinous adhesions were 





































































grade (e2 and f2). *P < 0.05 compared with control group; §P < 0.05 compared with PLLA 
group. Reproduced with permission;[114] Copyright 2015, Elsevier B.V.  
 
Biomaterials-associated bone tissue engineering refers to the construction of an artificial 
implant which can accelerate bone vascularization and mineralization, therefore resulting the 
reconstruction of injured or diseased bones.[77, 118, 151] Kang et al.[122] proposed a novel 
therapeutic design which embedded and delivered two growth actors simultaneously in core-
shell fibers in combination of mesoporous bioactive glass nanospheres (MBNs), which acted 
as drug carriers and meanwhile enhanced the apatite-forming ability and mechanical properties 
of the scaffolds. FGF18-loaded MBNs and FGF 2 were co-encapsulated into the core section 
of PCL/PEO fibers to achieve an earlier release of FGF2 for cell proliferation and angiogenesis 
and later release of FGF18 for osteogenesis. Both growth factors were sustainably released over 
65 days owing to the protective PCL shell. In vitro rat mesenchymal stem cells study presented 
significantly increased cell proliferation, ALP activity and expression of bone-related genes 
(Col I, ALP and OPN) and cellular mineralization on the composite fibrous scaffolds. When 
implanted in rat calvarium defects for 6 weeks, FGF2/FGF18 loading substantially increased 
the hard tissue ingrowth regions, which was evidenced by the highly increased bone volume 
and bone surface density from micro-CT images. In the study of Weng et al.[156], ultralight 3D 
fibrous aerogels composed of electrospun PLGA/collagen/gelatin fibers and Sr–Cu co-doped 
bioactive glass fibers were constructed by combining electrospinning and freeze-drying 
methods for cranial bone defect healing (Figure 11a). Heptaglutamate E7 domain specific 
BMP-2 peptides were further conjugated onto the optimized scaffolds for osteoinductive feature. 
In vitro release study suggested that 90% of the peptide was released within the first week 





































































2 peptide and bioactive ions (Ca2+, Si4+, Sr2+ and Cu2+) from bioglass fibers can work 
synergically to enhance bone healing and defect closure as the in vivo results showed an almost 
3-times higher (20 mm3 v.s. 7 mm3) regenerated bone volume in comparison to non-peptide 
group after treatment for 8 weeks (Figure 11c). Moreover, µ-CT images were used to 
quantitatively confirm that the high‐ density bone mineral covered more than half of the cranial 
defect after 8 weeks in E7-BMP-2-loaded group. 
Electrospun scaffolds displayed favorable advantages in musculoskeletal tissue regenerations 
that required intensive vascularization and possible specific configuration, such as alignment. 
Co-loading of multiple therapeutic agents could efficiently enhance the treatment efficacy and 
avoid the side effects maximally. Specifically for bone tissue regeneration, vascularization and 
further mineralization could be both achieved by co-loading of angiogenic factors and bioactive 
agents that induced biomineralization. Moreover, large volume scaffolds that closely mimic the 
native tissue and organs could be feasibly created by combining electrospinning and other 
fabrication techniques. Nevertheless, the produced scaffolds still have limited applications in 







































































Figure 11. (a) Schematic illustration on the formation of the 3D hybrid nanofiber aerogel and 
its structure at different length scales. (b) Loading of E7-BMP-2-FITC peptide on 3D aerogels 
and their cumulative release. (c) Representative planar radiographs of cranial bone defects at 4 
and 8 weeks after implantation: (c1/c4) No treatment (4w/8w). (c2/c5) 3D aerogel group 
(4w/8w). (c3/c6) Peptide-loaded aerogels group (4w/8w). Reproduced with permission;[156] 
Copyright 2018, John Wiley and Sons. 
 
3.2.3 Cardiac tissue engineering 
Cardiovascular diseases such as myocardial infarction (MI) or progressing heart failure have 





































































induce regeneration or prevent degeneration of myocardial tissue after MI is highly clinically 
relevant since cardiac tissues have limited regenerative capacity and the possibility to self-
renew and restore is rare.[158] The strategies of cardiac tissue regeneration have come up in two 
related directions: in vitro engineering and maturation of cardiac tissues followed by 
implantation, and development of methods for controllable drugs/siRNA/protein delivery into 
the heart.[159] Related to electrospun cardiac patches, earlier reports have emphasized on the 
mimicking of structural, mechanical and conductive properties of native cardiac tissues, aiming 
to facilitate the in vitro adhesion and maturation of cardiovascular cells.[160] Currently, 
combinational implementations of the two aspects, i.e., tissue regeneration and drug delivery, 
emerged as prospective approaches to achieve full recovery of the dysfunctional myocardium.  
It is well known that many growth factors and cytokines, such as VEGF and bFGF, are highly 
implicated in cardiomyocytes proliferation and survival and the maintenance of cardiac 
function.[161] However, their clinical uses were severely restricted by the fast 
degradation/elimination from the biological environment. Drug-loaded electrospun cardiac 
patches were thus expected to achieve sustained release in local area and further help restore 
the myocardium function. Lakshmanan et al.[87] embedded two angiogenesis growth factors 
(VEGF and bFGF) into a blend polymeric scaffold to promote vascularization for functional 
cardiac regeneration. The encapsulated VEGF and bFGF were sustainably released over 300 h 
and efficiently rescued cells from hypoxic stress for both in vitro chemical hypoxia model and 
in vivo ischemic model. In an acute in vivo rabbit acute myocardial infarction (AMI) model, the 
dual-growth factor releasing patches accelerated neovascularization and functional recovery of 
the ischemic heart. In another study, VEGF was confined within PCL/gelatin fibers through co-





































































Gene therapy was combined with electrospun patches as well to explore the potential to remodel 
dysfunctional heart tissues after MI. Gu et al. [68] incorporated recombinant adeno-associated 
virus (AAV) vectors into PEUU and PEEUU fibers by both blend and co-axial electrospinning 
methods (Figure 12a). AAV encoding green fluorescent protein (GFP) from co-axial fibers can 
be stably released over 2 months (Figure 12b). After implantation in the rat left ventricular 
lesions after MI, the fibrous cardiac patches exhibited extensive cellular infiltration and the 
AAV-GFP-loaded patches showed higher gene expression compared to the AAV-alone 
injection without support and patches without AAV (Figure 12c). In addition, both α-SMA and 
cardiac troponin T positive cells could be successfully transduced by the cardiac patch 






































































Figure 12. (a) SEM images and schematic illustrations on AAV encapsulation strategies of 
different scaffolds. (1) Cross section, scale bar, 10 µm; (2) surface, scale bar, 20 µm. (b) Release 
profiles of AAV DNA from scaffolds. *P < 0.05 compared with PEUU solid fibers. (c) 
Representative composite views of cross-sections of infarcted rat hearts harvested at 12 weeks, 
and stained by Masson's trichrome for (1) direct injection of AAV9-cmv-GFP, (2) PEEUU 





































































material areas. Scale bars, 2 mm. Reproduced with permission;[68] Copyright 2017, Elsevier 
B.V. 
 
Another key aspect of mimicking the native myocardium is to mimic the conductive properties, 
which are responsive for coordinated propagation of electrical signals to produce synchronous 
contractions that pump blood forward.[163] Conductive materials, such as carbon nanotubes 
(CNTs) and polyaniline (PANI), were incorporated as the “therapeutic agents” in these cases to 
form the conductive network in the scaffolds.[160d, 164] Liu et al.[164] loaded up to 6% of CNTs 
into highly aligned PEG-PLLA copolymer (PELA) fibers through both blend and co-axial 
electrospinning. In vitro cardiomyocytes culture indicated that scaffolds containing higher 
ratios of CNTs could favorably maintain the cell viabilities, induce the cell elongation, 
accelerate the production of sarcomeric α-actinin and troponin I, and enhance the synchronous 
beating of cardiomyocytes. By comparing the blend and core-shell fibers, they concluded that 
core-shell fibers with 5% of CNTs could beneficially support the cardiomyocyte proliferation 
with a generation of organized contractile proteins and a pulsation frequency close to that of 
the atrium without external electric stimulation. Similarly, Wang et al.[160d] blended up to 3 wt% 
of PANI into PLA fibers to construct fibrous nano sheets with improved electrical conductivity 
and enhanced cardiomyocytes maturation and spontaneous beating for cardiac tissue 
regeneration and cardiomyocytes-based 3D bioactuators. 
A recent study firstly reported the electrospinning of decellularized porcine cardiac ECM to 
fabricate well-defined cardiac scaffolds, which preserved the unique collagenous composition, 
microstructure, mechanical performances, bioactivity, and biocompatibility of cardiac 
ECM.[165] However, other functions such as electrical conductivity have not been explored yet. 





































































between synthetic scaffolds and native ECM by integrating multiple functions into the well-
defined cardiac scaffolds for better resemblance.  
 
3.2.4 Nerve tissue regeneration  
The application of electrospun scaffolds extends to both peripheral nerve injury,[76, 88, 101, 166] 
and central nervous system injury,[28a, 167] which consists of traumatic brain injury [168] and 
spinal cord injury.[33b, 91, 169] Those neurodegenerative diseases and traumatic nerve injuries 
vastly deteriorate the life quality and proper treatment methods are yet missing. As the nerves 
have limited capacity to spontaneously regenerate after traumatic injury, innovative strategies 
are being perused to promote the functional repair. The standard treatment can be summarized 
as "support and therapeutic", which is the combination of localized delivery of therapeutic 
molecules along with specialized architectures to support axonal growth and conformal 
repair.[170] Earlier studies have already demonstrated that micro- and nano-scale fibrous 
substrates could enhance neurite outgrowth,[171] neuronal maturation,[172] and neuronal 
differentiation.[173] And aligned fibers could guide the neuron cells to elongate along the major 
axis and form orientated cellular morphology.[166a, 174] Furthermore, drug-loaded electrospun 
scaffolds can function as both the drug carriers and the protective dressings for nerve systems, 
and then beneficially facilitate the neural tissue repair.  
Suzuki et al.[88] studied the capacity of electrospun PCL membrane to continuously deliver 
methylcobalamin to the peripheral nerve injury site for nerve regeneration. Evidenced by the in 
vitro drug release and in vivo rat sciatic nerve crush injury model, sustained release of 
methylcobalamin over 8 weeks sufficiently promoted the recovery of the motor and sensory 
function, the recovery of nerve conduction velocity, and the promotion of myelination. Naseri-





































































coated with citalopram-loaded gelatin nanoparticles. The citalopram-releasing scaffolds were 
further implanted in a rat sciatic nerve defect model to evaluate the potential for neural 
regeneration. The sciatic functional index (SFI) value corresponding to the drug releasing 
scaffolds was −34.23 ± 4.15 at 60th days, whereas −55.03 ± 3.16 for blank scaffolds, implying 
the significantly promoted treatment progress through immobilization of drug-loaded 
nanoparticles.  
In addition to the small molecular drugs, biomacromolecules such as growth factors and 
peptides were also proved beneficial to the adhesion, expansion and maturation of neural cells. 
Li et al.[33b] embedded stromal-cell-derived factor-1α (SDF1α) in radially aligned collagen/PCL 
fibermats to provide directional cues, i.e., alignment topography and biological gradients, for 
recruitment of neural stem cells from the central canal region to the lesion site to repair spinal 
cord injury. A collagen-binding domain (CBD) was conjugated onto SDF1α for stronger 
binding to collagen, resulting in gradient and sustained release of SDF1α over 7 days. The 
gradient distribution of chemokine SDF1α and the radical aligned topography both contributed 
to the elongation of cells along the radical direction and highly accelerated cell migration from 
periphery towards center area. The produced materials were proved to be solid matrices for 
neuronal cell migration, differentiation and axonal outgrowth as well as bridges to guide axons 
extension to establish functional connections. Zhang et al.[101] loaded nerve growth factor 
(NGF) into conductive composite scaffolds through co-axial electrospinning, and further 
studied and assessed the synergistic eff ects of electrical stimulation and NGF on the neuron 
growth. It was found that the aligned structure, electrical stimulation and NGF release all 






































































Aiming for bridging the defected nerve with a gap larger than 10 mm, Zhu et al. [76] produced 
a tubular PCL nerve conduit composed of electrospun microfibers. Peptide self-assembled 
RGD and YIGSR layers were non-covalently bonded to the obtained PCL fibers and were 
expected to improve the biocompatibility of hydrophobic PCL fibers (Figure 13a, b). In vitro 
cell culture demonstrated that RGD and YIGSR synergistically enhanced the cellular 
proliferation and neurite outgrowth. Sciatic nerve defects were surgically created on adult male 
Sprague-Dawley rats and then sutured with surface-modified PCL conduits to evaluate the in 
vivo axonal regeneration (Figure 13c). The morphometric analysis of the harvested nerves after 
12 weeks displayed that the PCL conduits with RGD/YIGSR coating exhibited equivalent and 
comparable healing effect to auto grafts regarding the total area of regenerated axons, the total 
number of myelinated axons, and the diameter of myelinated axons. By comparing with the 
RGD-only and YIGSR-only group, they concluded that the co-existence of RGD and YIGSR 







































































Figure 13. (a) Structure characterization of PCL and peptide modified PCL tubular grafts: (1) 
Optical image and (2) SEM images for the cross-section. Fluorescence microscopy image of 
cross-section of tubular scaffold and film scaffold for (b1, 4) FITC-labeled PCL-RGD; (b2, 5) 
rhodamine-labeled PCL-YIGSR; (b3, 6) both FITC-labeled RGD and rhodamine-labeled 
YIGSR together. (c) The gross view of the regenerated nerve, toluidine blue staining of 
regenerated axons, TEM of regenerated axon, and myelin sheath at middle portion in all groups 
at 12 weeks after surgery: (c1, 6, 11, 16) autograft group, (c2, 7, 12, 17) control group, (c3, 8, 
13, 18) RGD group, (c4, 9, 14, 19) YIGSR group, and (c5, 10, 15, 20) RGD/YIGSR group. 
Reproduced with permission;[76] Copyright 2017, John Wiley and Sons. 
 
Besides traditional drugs and biomolecules, novel materials such as graphene oxide were 
employed in nerve tissue engineering as well.[176] Directional guidance, inherent regulation via 
biomolecules and synergy effects from multiple factors are the main themes of the current 
research in nerve tissue engineering. However, matched biodegradation profiles of scaffolds 
were mostly missing though intensive studies have focused on the grafts fabrication and in vitro 
and in vivo assays. 
 
3.2.5 Blood vessel regeneration 
Cardiovascular diseases, such as coronary artery and peripheral vascular diseases still remain 
as the prevalent cause of death due to the continued growing of aged population world widely. 
[31b, 33a, 72] Artificial vascular grafts to replace diseased or narrowed vessels have been 
recognized as the clinical focus owing to the limited donation of autologous vessels. Although 
commercial products such as Dacron and Teflon have been successfully applied as large 





































































hyperplasia could be initiated in case of small diameter vascular grafts (SDVGs) (< 6 mm), by 
the surface thrombogenicity and low compliance of Dacron and Teflon.[177] The development 
of SDVGs is still clinically necessary. In recent years, electrospun fibrous scaffolds were 
intensively investigated to fabricate SDVGs due to its feasibility for generating a tubular and 
porous structure by collecting on a rotating mandrel. Moreover, the electrospun scaffolds can 
be easily functionalized to meet the clinical requirements for SDVGs, for instance, to prevent 
thrombosis, to inhibit hyperplasia (over-proliferation of smooth muscle cells) and to promote 
rapid endothelialization for vascular regeneration.[33a, 81] 
Punnakitikashem et al.[81] produced multifunctional tubular BPU scaffolds containing 
dipyridamole to achieve full generation of small diameter vessels since dipyridamole was 
reported to not only inhibit the thrombosis formation and over-proliferation of smooth muscle 
cells, but also promote and stimulate the proliferation of vascular endothelial cells. The 
sustained release of dipyridamole extended to 91 days, which effectively increased the human 
blood clotting time, reduced the human platelet deposition, inhibited the human aortic smooth 
muscle cell proliferation and finally improved the proliferation of human aortic endothelial cells.  
Surface modification, such as heparin immobilization, represents another crucial strategy to 
functionalize the tubular fibrous scaffolds for SDVGs regeneration. [33a, 72, 178] In the study of 
Yao et al.[33a], heparin was immobilized onto PLC/chitosan electrospun fibers through ionic 
bonding, resulting in stable release over 37 days to improve the hemocompatibility. When 
implanted in rat abdominal aorta for 1 month, the scaffolds showed well anti-thrombogenic 
effect and enhanced in-situ endothelialization. Qiu et al.[72] immobilized heparin onto 
polycarbonate-urethane (PCU) fibrous scaffolds with plasma-treated fiber surface (Figure 14a). 
It was found that plasma treatment could more effectively introduce amine groups for 





































































adsorption. The patency of heparin-conjugated PCU grafts was testified by implanting in the 
left common carotid artery of Sprague-Dawley rats. As shown in Figure 14b, more visible 
microvessels can be observed around the heparin-coated grafts harvested after both 2 and 4 
weeks in vivo, indicating enhanced vascularization. More SMA+ cells migrated through the 
outer layer of PCU-heparin grafts, suggesting promoted cell infiltration (Figure 14c). The 







































































Figure 14. (a) Structural and mechanical characterizations of PCU vascular graft. SEM images 
of (1) side and (2) top view of an PCU graft. SEM images before and after the plasma treatment 
in the (3, 5) inner (luminal) and (4, 6) outer surface of the graft. (7) PCU grafts of various inner 
diameters (1 mm and 6 mm). (8) Bending of a 6 mm-diameter PCU graft. (9) Mechanical 
characterizations among control (untreated), aminolyzed, polydopamine (PD)-coated, plasma-





































































= 30 µm in 3, 4, 5, 6. (b) Representative images of graft explantation of control group and 
plasma-treated group after 2 weeks (1, 3) and 4 weeks (2, 4) and patency of the grafts were 
compared in (5). (c) Cross-section immunostaining of PCU plasma-control and plasma-heparin 
grafts after 2 and 4 weeks in vivo. Immunostaining for SMA (green), cell nuclei (DAPI, blue). 
Scale bar = 100 µm. Reproduced with permission;[72] Copyright 2017, Elsevier B.V. 
 
Electrospun scaffolds-based gene therapy was also developed to remedy cardiovascular disease 
in the study of Zhou et al.[66] A bilayer tubular scaffold, consisting of PCL/gelatin fibers as the 
outer layer and miRNA-126 complexes-loaded PELCL fibers as the inner layer, was produced 
through dual-power electrospinning and emulsion electrospinning, respectively. The other layer 
was designed to physically maintain the configuration, and the gene-loaded inner layer was 
expected to regulate the cellular behaviors of vascular endothelial cells. Attributed to the multi-
barriers in the bilayer scaffolds, miRNA-126 was sustainably released over 56 days. The stably 
released miRNA-126 was proved to highly promote the proliferation of human umbilical vein 
endothelial cells and down-regulate the expression of SPRED-1, which could diminish the 
transmission of intracellular angiogenic signals generated by VEGFs and FGFs. In vivo 
examination indicated extensive cell infiltration and highly enhanced ratio of endothelialization 
after implantation of the gene-loaded samples, in comparison to the pure polymer samples. The 
well-preserved miRNA activity and well-maintained patency of bilayer vascular graft 
suggested its prospective application in vascular tissue reconstruction. 
Instead of fabricating a graft for in-situ tissue regeneration, Liu et al.[177] engineered a blood 
vessel graft in ex vivo conditions by co-cultivating vascular endothelial and smooth muscle cells 
onto layered electrospun membrane with plasmid DNA encoding bFGF and VEGF integrated, 





































































Electrospun fibrous membrane can also found its application in vascular surgery. To prevent 
vasospasm and repair vascular tissue after vascular surgery, Zhu et al.[34a] produced papaverine-
loaded PLLA/PEG scaffolds with adjustable drug releasing rate and degradation period. The in 
vivo healing efficiency was certified by warping around the incision sites in the vascular 
anastomosis of the rabbit neck. After 2 weeks, vessels implanted with drug-loaded PLLA/PEG 
membranes had no shrinkage in diameter, untraceable hyperplasia and minimized inflammation, 
compared to PLLA-alone group. Normal vessel morphology with regularly arranged vessel 
walls were observed on drug-loaded group, indicating great antispasmodic effect and potential 
to inhibit vasospasm and repair vascular damage. 
 
3.3 Cancer Therapy 
Cancer is a leading cause of mortality worldwide. The heterogeneity and adaptive resistance of 
cancer are the major challenges that are difficult to surmount through traditional chemotherapy. 
The fast-growing nano-medicine technology, which endowed passive or active targeting 
capacity to cancer cells, can significantly improve the pharmacokinetic profiles of drugs and 
further enhance the drug accumulation in tumor, offering new strategies to treat cancer. 
Electrospinning has emerged as a highly competitive technology in cancer research, in view of 
the tunable surface morphology for modulating drug pharmacokinetics and the robust loading 
capacity for combining various therapeutics.[59b] A variety of anticancer agents ranging from 
small molecular drugs to aptamer and RNA can be incorporated into electrospun fibers by 
simultaneous encapsulation and surface modification, and then undergo a diffusion-controlled 
or degradation-controlled release profiles depending on the materials and fabricating 





































































By the virtue of the high surface-to-volume ratio of nanofibers, enhanced local topographic 
interactions between the substrates and components (e.g., microvilli and filopodia) on cellular 
surface can also be achieved.[180] Thus, electrospun scaffolds modified with specific biomarker 
molecules own great potential for capturing the circulating tumor cells (CTCs) and cancer 
detection.[181] Furthermore, compared with other nanostructures, the similarity of the prepared 
fibers to the collagen fibrils in the ECM can offer better scaffold- and matrix-based 2D or 3D 
models to enhance the cell–cell and cell–matrix interactions than other nanostructures, which 
endow the electrospun scaffolds with distinguish advantage in cancer treatment by regulating 
the cancer cell behaviors.[182] This resemblance can be further improved by modifying the fibers 
with ECM proteins or peptides.[59b, 183] For example, Rabolt et al.[183] found that covalently 
conjugating perlecan domain IV (PlnDIV) peptide onto the electrospun PCL/gelatin composite 
scaffolds significantly enhanced the adherence and infiltration of metastatic prostate cancer 
cells towards the electrospun substrates. In this section, we will introduce the recent 
developments of electrospun scaffolds in the application of cancer research mainly on the 
cancer therapy and CTCs detection and capture. 
 














C2C12 cell, in vitro 
 
 
Sustained release > 6 d; 
~ 25% more decrease in cell proliferation 






HepG2 cell, in vitro 
and in vivo 
20-fold higher cytotoxicity than free drugs 
after 72 h; 
More necrosis and apoptosis; 








































































C6 glioma cells 
 
 
Sustained release > 80 d; 
~ 44% smaller tumors in comparison to free 
















Sustained release in a linear profile > 90 d; 
significant increase in median recurrence-







cell, in vivo 
limited injury to neighboring tissue and 






SMMC7721 cell,  
in vitro and 
hepatocarcinoma 
H22 cell, in vivo 
Sustained release for 12 d ; 
~ 40% decrease in cell proliferation 










PCL MCF-7 breast cancer 
cell 
~40% increase in cell inhibition compared 
with control scaffold; 
Sustained release > 21 d; 
[191] 
Paclitaxel and 
MMP-2 RNAi  
PLGA U87MG-luc2 cell Significant synergistic anticancer effect; [192] 
PCL: poly(ɛ-caprolactone); PLA: poly(L-lactic acid)-poly(ethylene glycol); HA: hyaluronic acid; PGC-C18: 
poly(glycerol monostearate-cocaprolactone); PEG: poly(ethylene glycol); shRNA: short hairpin RNA. 
 
3.3.1 Scaffolds-based drug delivery systems for cancer therapy 
As previously mentioned, various anticancer reagents obtained sustained release profile and 
prolonged activities by encapsulating within electrospun substrates. The fabricated drug-loaded 
scaffolds can be implanted or injected into the tumor bed after tumor localization.[193] For 
instance, Ramachandran et al.[193a] demonstrated that implanting the Temozolomide-loaded 
PLGA-PLA-PCL fibrous scaffolds into the rat with orthotopic glioma caused long-term (> 4 





































































PLA-PEG scaffolds to treat H22-tumor bearing mice and studied the effect of the fiber lengths 
on the biodistribution of fibers in the tumor. They found that longer fiber lengths led to a higher 
tumor accumulation and retention, but less diffusion. 
However, two major limitations restricted the clinical application of electrospinning for cancer 
treatment. Firstly, most of the drug release behaviors relied on the passive diffusion, lacking 
the controllability for necessary drug concentrate to kill cancer cells.[40] Therefore, introducing 
stimuli-responsive blocks to endow the electrospun scaffolds with on-demand release capacity 
is a basic requirement in recent studies.[40, 194] The other concerns related to the insufficient 
cancer cellular uptake of the therapeutics. Due to the susceptibility to multidrug resistance for 
most of the cancer cells and the inherent properties of some therapeutics (such as the negative 
charges of oligonucleotides) that is unfavorable for cancer cell internalization, direct drug 
delivery in a “fiber-to-cell” manner is insufficient for effective cancer treatment.[195] 
Incorporation of functional nanoparticles into the electrospun scaffolds is a promising strategy 
to solve the aforementioned problems, in view of the well-studied stimuli-responsive capacities 
to physical stimuli and the additional surface for targeting molecules conjugation.[194] Kim et 
al.[196] encapsulated magnetic nanoparticles into DOX-loaded thermo-sensitive polymer N-
isopropylacrylamide (PNIPAAm) fibers via electrospinning to develop a magnetic 
hyperthermia-controlled drug release system (Figure 15a). The self-generated heat under the 
alternating magnetic field led to the “on-off” drug release from the fibers. Attributed to the 
synergistic effect of hyperthermia and chemotherapy, 70% of human melanoma cells died 
within 5 min. Ghavaminejad et al.[197] then employed catecholic polymer nanofibers to carry 
and bind the IONPs and bortezomib drugs for synergistic effects from hyperthermia and pH-





































































Moreover, the formed hierarchical nano-in-nano architectures owned improved 
biocompatibility and cargo release tunability.[198] Qiu et al.[199] incorporated the DOX-loaded 
MSNs into PLLA nanofibers via electrospinning, and the obtained PLLA/DOX@MSNs 
nanofibrous scaffolds showed improved thermal stability than PLLA nanofiber and better anti-
proliferation efficacy to Hela cells than the MSNs-free counterparts. An implantable DOX-
loaded micelle-in-nanofiber device was developed via co-axial electrospinning to treat 4T1 
murine breast tumor in nude mice (Figure 15b).[121] The folate-conjugated PCL-PEG micelles 
with DOX were loaded within PVA core region and further shielded by cross-linked gelatin 
shell. During the degradation of the nanofiber matrix, the micelles were sustainably released 
from the matrix and accumulated into tumor tissues by interstitial transport and enhanced 
permeation and retention (EPR) effect, then finally internalized by tumor cells via folate 
receptor-mediated endocytosis. By using this nanodevice, both the side effects of anticancer 
drugs and the administration frequency can be greatly reduced, while the therapeutic efficacy 
was maintained. 
In addition to the conventional nano- or micro- particles, adenoviral (Ad) can also be used to 
construct nanocomplexes by electrospinning.[200]  Park et al.[200a] demonstrated that Ad can be 
ionically cross-linked with chitosan-PEG-folate polymer via electrospinning. The formed 
Ad/chitosan-PEG-folate nanocomplexes maintained the biological activity as naked Ad. 
Moreover, for the folate receptor-expressing KB cells, the transduction efficiency of the Ad-
based nanocomplexes was higher than the receptor-negative U343 cells. Besides that, this 






































































Figure 15. (a) The magnetic nanoparticles incorporated temperature-responsive 
poly(NIPAAm-co-HMAAm) nanofibers for DOX release. Reproduced with permission;[196] 
Copyright 2013, John Wiley and Sons. (b) Schematic illustrations on the fabrication of the 
DOX-loaded micelle-in-nanofiber device and the delivery process of these folate-modified 
DOX-loaded micelles by EPR effect and finally to tumor cells. Reproduced with 
permission;[121] Copyright 2015, American Chemical Society. 
 
3.3.2 Biosensors for detection and capture of circulating tumor cell (CTCs)  
The detection and capture of cancer cells, especially the CTCs from the patient blood rely on 
the specific and sensitive recognition of the overexpressed markers on the surface of cancer 
cells.[201] However, the low abundance and heterogeneity of the cancer cells in blood 
environment prevent reliable analyses.[202] Owing to the tunable morphologies of electrospun 
fibers that can enhance the local topographic interactions with cancer cells, specific biomarkers 





































































antibody binding with improved accuracy and sensitivity.[59b, 203] Various proteins on cancer 
cell surface have been adopted as biomarkers for cancer cell recognition, such as EGFR2 or 
ErbB2 and carcinoma antigen-125.[36, 181b, 181d] For instance, Ali et al.[36] fabricated electrospun 
mesoporous ZnO nanofibers with femtomolar sensitivity for breast cancer diagnostics. After 
oxygen plasma treatment, the carbon-doped ZnO fibers were available for the conjugation of 
the antibody of ErbB2 (anti-ErbB2), and they showed high immunoelectrode to ErbB2 with an 
association constant of 404.8 kM−1 s−1. 
The overexpression of tumor matrix proteins, such as matrix metalloproteinases 9 (MMP-9), 
can also be used as the biomarker for cancer cell detection. Han et al.[204] prepared a hydrogel-
framed polystyrene/poly(styrene-alt-maleic anhydride) by electrospinning, and immobilized 
the fiber with fluorescein isocyanate (FITC)-labeled MMP-9 specific peptides. This enzymatic 
cleavage-based detection strategy can achieve a detection limit of 10 pM with a response time 
of 30 min. 
The CTCs usually circulated in the blood stream during the tumor metastatic process, which 
can be regarded as “liquid biopsies” of the primary tumors and the specific mechanism for 
cancer metastasis.[201, 205] Zhang et al.[181d] fabricated horizontally packed ultra-long calcinated 
TiO2 nanofibers (TiNFs) through electrospun titanium n-butoxide (TBT)/PVP fibers (Figure 
16a). Compared with the vertically oriented silicon nanopillars, the horizontally oriented 
architecture of TiNFs can better mimic the ECM condition, thus leading to further improved 
cell–substrate interactions. Then the streptavidin was immobilized onto the TiNFs for the 
follow-up conjugation of the biotinylated epithelial cell adhesion molecule antibody (anti-
EpCAM). Based on the enhanced local topographic interactions and the anti-EpCAM/EpCAM 
biological recognition, this TiNFs showed considerable capture efficiency to the CTCs in both 





































































patients. To avoid the impurities caused by non-specific captured cells, Hou et al.[206] used a 
transparent PLGA-nanofiber-embedded nanovelcro chip to replace the non-transparent silicon 
substrate (Figure 16b). Then anti-CD146 antibody was used as melanoma-specific capture 
agent to conjugate onto the fiber. The nanovelcro chip can efficiently capture the metastatic 
cells from the blood samples of stage-IV melanoma patients. A Leica LMD7000 microscope 
equipped with a 355 nm laser microdissection setup was used to cut the PLGA nanofibers for 
single cell isolation. The obtained cell sample subsequently underwent the whole-genome 
amplification and specific PCR amplification for the final Sanger g DNA sequencing. This laser 
microdissection-based single-CMC detection strategy offered an opportunity to investigate the 
gene-related variations for cancer diagnose.  
  
Figure 16. (a) Schematic illustrations of epithelial-cell adhesion-molecule antibody (anti-
EpCAM) modified TiO2 electrospun nanofibers for cancer cell capture. Reproduced with 
permission;[181d] Copyright 2012, John Wiley and Sons. (b) Schematic illustrations of anti-
CD146 antibody-grafted PLGA nanofiber-embedded nanovelcro chip for capturing circulating 
tumor cells. (b1) Fabrication of the nanovelcro substrate. (b2) Chemical conjugation of 
streptavidin for anchoring of biotinylated anti-CD146. (b3) Schematic illustrations of the 
mechanism of the nanovelcro CMC chip. (b4) Scheme of the laser microdissection-based 






































































In summary, electrospun fibrous scaffolds have evolved from a drug reservoir for sustained 
drug release to a powerful and combinational therapy platform with high compatibility that can 
bridge chemotherapy, thermotherapy and post-surgery tumor treatment. Moreover, new 
therapeutic strategies, such as the tumor guide device, have shown great value for clinical 
translation. However, most of the studies are still restricted on the preclinical level, and the 
systemic investigation and evaluation on the immunogenicity, metabolic cycle and safety of the 
scaffolds are still limited. Besides that, the studies of physical parameters-related patient 
compliance, such as the effects of length, tensile strength, structure and morphology on the 
retention and distribution in the tumor, still require tremendous data support.  
 
4. Conclusions and Future Perspectives 
4.1 Conclusions and remarks 
Electrospun drug delivery vehicles have emerged as one of the essential applications of 
electrospinning in the biomedical field. The high diversity in source materials, drug loading 
techniques and the resultant morphological, physiochemical and biological performances of the 
obtained drug-loaded systems all contributed to the widespread implementations. By choosing 
appropriate polymer matrix, the drugs can be released in seconds, minutes, hours, days or 
months according to diverse requirements in oral/transdermal drug release, tissue regeneration 
or anti-recurrence of tumors. Moreover, by varying the drug loading approaches, loaded drugs 
can be released in rapid, sustained, biphasic or zero-order fashion to meet the timely-varied 
demands during the difference phases of a healing or regeneration process of in vivo 
environments. By adding another or more drug delivery vehicles either in particulate 
formulations or another fibrous formulation into the main platform, multifunctional drug 





































































complex in vivo conditions. Additionally, pH, temperature, light, electrical or magnetic field 
responsive polymers were employed to further endow the drug carrier systems with controlled 
or multi-staged release features upon exposure to the corresponding stimuli.   
Compared to the traditional drug formulations, electrospun fibrous formulations could greatly 
enhance the solubility of water-insoluble drugs due to the highly increased solid dispersion 
induced by high surface-to-volume ratio of electrospun fibers, resulting in faster drug dissolving 
in oral cavity or higher diffusion rate through skin. As an implantable drug-eluting device, apart 
from being the template to support and accommodate the cell proliferation and differentiation, 
electrospun scaffolds can effectively prevent the infection or promisingly enhance the cellular 
metabolism activities through releasing of growth factors or other biomolecules as well. For 
anti-cancer treatment, the possibility to load multiple therapeutics enables the combinational 
therapeutic strategy simultaneously, such as hyperthermic-chemotherapy and photothermal-
chemotherapy. The electrospun inorganic fibers loaded with biomarkers also represented a new 
strategy to fabricate immunosensor with hypersensitivity for disease diagnosis.   
Overall, electrospun architectures undoubtedly have become multifunctional platforms carrying 
active ingredients to promisingly address the existing medical challenges.  
 
4.2 Future perspectives 
Nevertheless, there is still a great gap between the lab validation to clinical trials and then the 
actual commercialization. Currently, no electrospun products have been approved by FDA and 
only few clinical trials have been documented to further testify the function of the designed 
drug delivery platforms.[207] In a double-blind, randomized and placebo-controlled clinical trial 





































































treatment.[208] Apparently, although in vivo studies have already been conducted to verify the 
curing efficacy under the complex in vivo environments, the huge difference on size and 
metabolism systems between human and small animals used in vivo study could cause 
unexpected results during the clinical trials.[209] Furthermore, both economic burdens and 
limitations in production rate hindered the large-scale clinical trials in human.[210] Enormous 
efforts are still demanding in this aspect.  
Another limitation for actual commercialization is the low yield of the laboratory 
electrospinning apparatus. Although high throughput electrospinning systems, such as 
needleless electrospinning and multi-needle electrospinning are already capable of scaling up 
the fiber production, the study of drug-loading systems from those equipment were rarely 
reported.[211] Several issues restrict the scaling-up and further applications in biomedical fields. 
For instance, the massive organic solvent evaporation during the high-throughput production 
could cause severe environmental risk and the solvent residue may compromise the therapeutic 
effect.[210] Additionally, quality control and high reproducibility is also challenging in high-
throughput electrospinning due to the massive charge accumulation during the long-time 
process.[211] The scale-up process may generate drug delivery systems with distinct drug release 
profiles and physiochemical performances due to the mutual influence among the multi-
electrodes, and this long-term charges accumulation. Although some companies have started to 
work on these problems by designing new spinneret configurations, there is still a long way to 
go for commercialization of biomedical products.   
As a multi-disciplinary subject associated with materials science, pharmaceutical engineering 
and life science, more dialogues among scientists in diverse disciplines should be opened-up 
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The table of contents description 
 
Drug-loaded electrospun architectures are gaining increasing attention in various biomedical 
applications. By carefully choosing materials/drugs and drug loading techniques, electrospun 
structures with adjustable topography, tunable porosity, high surface area, and controllable drug 
release behaviors can be manufactured for biomedical applications, such as simple drug 
delivery systems, tissue engineering and cancer therapy. The recent progresses are thoroughly 
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